Feline Coronavirus and FIP

Overview and Taxonomy of Feline Coronavirus (FCoV) and Feline Infectious Peritonitis (FIP)

The Viral Agent: Classification and Phylogenetic Context

Feline coronavirus (FCoV) is an enveloped, positive-sense, single-stranded RNA virus belonging to the genus Alphacoronavirus within the family Coronaviridae, order Nidovirales [22, 46]. This taxonomic placement situates FCoV within the same subfamily (Coronavirinae) as several other significant mammalian pathogens, yet distinguishes it from the Betacoronavirus genus, which includes Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2), Middle East Respiratory Syndrome Coronavirus (MERS-CoV), and human coronaviruses OC43 and HKU1 [21, 28]. The Alphacoronavirus genus also encompasses human coronavirus 229E (HCoV-229E) and HCoV-NL63, as well as canine coronavirus (CCoV) and porcine transmissible gastroenteritis virus [20, 28]. This close phylogenetic relationship, particularly between FCoV and CCoV, has profound implications for viral evolution and the emergence of novel pathogenic strains through recombination events [5, 24].

The FCoV genome, approximately 29–31 kilobases in length, is the largest among RNA viruses and encodes several structural and non-structural proteins. The canonical genomic organization is 5′-replicase (ORF1a/1b)-Spike (S)-Envelope (E)-Membrane (M)-Nucleocapsid (N)-3′-UTRand includes accessory genes (ORF3abc, ORF7ab) that are critical for understanding pathogenicity [22, 26, 46]. The S protein, a large type I transmembrane glycoprotein that forms the characteristic crown-like peplomers on the virion surface, is the principal determinant of cell tropism, receptor binding, and viral entry [46]. The M protein, the most abundant structural component, is essential for virion assembly and budding, while the N protein packages the genomic RNA into a helical nucleocapsid and plays roles in viral RNA synthesis and host immune modulation [6, 8]. The E protein, a minor component, is involved in virus assembly, release, and pathogenesis.

The Two Biotypes: Feline Enteric Coronavirus (FECV) and Feline Infectious Peritonitis Virus (FIPV)

A foundational concept in FCoV biology is the existence of two distinct biotypes, which are genetically and pathologically distinct but antigenically related: the ubiquitous, relatively benign feline enteric coronavirus (FECV) and the highly virulent, deadly feline infectious peritonitis virus (FIPV) [22, 26]. FECV is an enteropathogenic virus that primarily infects the mature enterocytes at the tips of the intestinal villi, leading to a mild, often subclinical, infection or self-limiting diarrhea, particularly in kittens [2, 8, 18]. Replication is largely confined to the gastrointestinal tract, and viral shedding occurs in the feces, facilitating the highly efficient fecal-oral route of transmission that sustains its endemicity in feline populations worldwide [18, 23].

In contrast, FIPV is not a distinct, exogenously transmitted virus but rather arises de novo within an individual cat infected with FECV through the acquisition of specific mutations that fundamentally alter its cellular tropism and pathogenicity [8, 22, 26]. This "internal mutation theory" posits that during the course of FECV replication, particularly in the face of a robust but ultimately aberrant immune response, the virus undergoes genetic changes that confer the ability to infect monocytes and macrophages efficiently [2, 26, 46]. This crucial shift from an enterocyte-tropic to a macrophagetropic phenotype enables the virus to disseminate systemically via the bloodstream, leading to the fatal immune-mediated disease known as feline infectious peritonitis (FIP) [4, 27, 47]. The transition from FECV to FIPV is a stochastic event, estimated to occur in approximately 5–12% of FCoV-infected cats, and is influenced by a complex interplay of viral genetics, host immune status, and environmental stressors [2, 18, 35].

The Two Serotypes: FCoV-I and FCoV-II

Beyond the biotypic classification based on pathogenicity, FCoV is also divided into two serotypes, type I (FCoV-I) and type II (FCoV-II), based on antigenic and genetic differences in the spike (S) protein [3, 13, 33]. These serotypes are believed to have diverged evolutionarily, with FCoV-I representing the original, more ancient feline alphacoronavirus, while FCoV-II is thought to have arisen from a recombination event between FCoV-I and canine coronavirus (CCoV), incorporating a large fragment of the CCoV S gene into the FCoV genomic backbone [3, 13, 33]. This recombination has endowed FCoV-II with a different receptor usage profile, specifically a high affinity for feline aminopeptidase N (fAPN), which is the primary functional receptor for serotype II [38, 46]. The receptor for FCoV-I remains incompletely characterized, though it is known to be distinct from fAPN, which has historically hampered the in vitro study of the more prevalent serotype I [15, 38].

Epidemiologically, FCoV-I is the dominant serotype circulating in global feline populations, accounting for 80–95% of infections in many regions, including North America, Europe, and Asia [3, 33, 48]. A large-scale molecular survey in China identified FCoV-I in 95.8% of FCoV-positive samples from both healthy and FIP-suspected cats, with FCoV-II comprising only 4.2% [3]. Similar predominance of FCoV-I has been documented in studies from Italy, the United Kingdom, and the United States [13, 32, 38]. Despite its lower prevalence, FCoV-II has been more extensively studied in vitro due to the relative ease with which it can be propagated in cell culture systems, such as Crandell-Rees Feline Kidney (CRFK) cells and Felis catus whole fetus-4 (Fcwf-4) cells, which express the fAPN receptor [15, 38]. This has created a knowledge bias, emphasizing the need for improved culture systems and reverse genetics tools for FCoV-I [11, 15, 19, 38].

The recent emergence of a highly pathogenic FCoV-CCoV recombinant, designated FCoV-23, responsible for a devastating FIP epizootic in Cyprus, has dramatically expanded our understanding of FCoV diversity and evolution [5, 24]. This novel strain possesses a minor recombinant region within the S gene, spanning the receptor-binding domain, that shows 96.5% sequence identity to the pantropic canine coronavirus NA/09 [5, 24]. The FCoV-23 virus has rapidly spread across the island, infecting cats of all ages, with an unusually high incidence of FIP and a notable increase in neurological presentations [5, 45]. Crucially, more than 90% of FIP cases in this outbreak harbor a near-cat-specific deletion in domain 0 of the S protein, which is hypothesized to be a key determinant of the heightened pathogenicity and altered cell tropism of this recombinant virus [5, 24, 36]. This discovery challenges the traditional view that FIP is strictly an endogenous, sporadic disease and demonstrates that a highly pathogenic, directly transmissible FCoV variant can emerge and cause widespread epizootics [5, 24].

Epidemiology, Transmission, and Risk Factors

FCoV is an exquisitely contagious virus and is considered endemic in domestic cat populations worldwide. Reported seroprevalence rates are highly variable, ranging from 4% to over 95%, depending on the population studied, with the highest rates consistently found in multi-cat environments such as shelters, breeding catteries, and rescue facilities [1, 29, 32]. A large-scale study of healthy pet cats in the United Kingdom reported an overall seroprevalence of 59.5% using a comprehensive serological screening approach [32]. In stray cat populations, seropositivity is often high; for instance, a seroepidemiological survey in Turkey found that 71% of seropositive cats presented with enteric signs, while 29% were diagnosed with FIP [28].

Transmission occurs primarily via the fecal-oral route, with indirect transmission through shared litter boxes, contaminated fomites (e.g., feeding bowls, bedding, and human hands), and, to a lesser extent, through direct contact with infected individuals or their feces [18, 23]. The virus is shed in high concentrations in the feces of infected cats, often for weeks to months, and can persist in the environment under favorable conditions, contributing to its rapid spread in communal living situations [37, 44]. Kittens born to FCoV-shedding queens are typically infected at a very young age, often becoming seropositive by 8–12 weeks of age, as maternally derived antibodies wane [18, 23].

Several key risk factors for FCoV infection and subsequent FIP development have been robustly identified. Multi-cat environments are the single most significant risk factor for acquisition of FCoV, with infection rates approaching 100% in some catteries [3, 17, 25, 29]. A nationwide study of 14,035 clinical samples from the United States found that cats under one year of age had significantly higher FCoV detection rates [16]. Age is a critical determinant: the incidence of FIP is highest in kittens and young adults, with the majority of cases occurring in cats under two years of age, and a disproportionate number of cases are reported in purebred cats [16, 18, 40]. A comprehensive analysis of risk factors in the US identified British Shorthairs as having an odds ratio of 2.81 for FCoV infection compared to mixed-breed cats [16]. Furthermore, male cats, particularly those that are intact, have been shown to have a slightly elevated risk of both FCoV infection and FIP development in several studies [7, 16]. Stress, concurrent infections (such as feline leukemia virus or feline immunodeficiency virus), and genetic predisposition are also thought to play significant roles in tipping the balance from benign FECV carriage to the development of fatal FIP after the crucial mutation event [23, 28, 43].

Host Range and Implications for Conservation

While FCoV is primarily a pathogen of domestic cats, its host range extends to numerous species within the family Felidae, including both wild and captive exotic felids [14, 39]. Feline infectious peritonitis has been documented in a wide array of non-domestic felids, including cheetahs (Acinonyx jubatus), tigers (Panthera tigris), lions (Panthera leo), mountain lions (Puma concolor), European wildcats (Felis silvestris), Pallas’ cats (Otocolobus manul), and, as recently confirmed, the Persian leopard (Panthera pardus tulliana) [10, 13, 14]. An outbreak of FIP in a cheetah population in a zoological collection exemplified the devastating consequences of introducing FCoV into a naïve group of highly susceptible animals, where the disease can decimate populations [14]. A retrospective molecular epidemiological study using hybridization capture and next-generation sequencing provided the first definitive evidence of natural cross-species transmission of FCoV-I between a domestic cat and a Pallas’ cat housed in the same room, highlighting the direct spillover risk posed by infected domestic cats to valuable captive breeding programs [13]. Surveys of captive non-domestic felids in Northern Italy have reported an overall FCoV prevalence of 7.9%, with infection rates varying dramatically between different facilities (from 0% to 60%), underscoring the importance of stringent biosecurity protocols to prevent the introduction of this virus into threatened and endangered populations [39]. The World Organisation for Animal Health (WOAH) recognizes FIP as a significant disease of concern in felids, and its emergence in novel hosts like the Persian leopard underscores the ongoing threat to wildlife conservation efforts.

Diagnostic Approaches: From Detection to Differentiation

Diagnosing FIP remains one of the most formidable challenges in veterinary medicine, as there is no single pathognomonic antemortem test that can definitively differentiate FIPV infection from a benign FECV infection [2, 7, 31]. The diagnostic approach relies on a multimodal strategy that integrates signalment, history, clinical signs, clinicopathological abnormalities, and specific laboratory tests.

Molecular Detection (RT-PCR and qPCR): Reverse transcription polymerase chain reaction (RT-PCR) and its quantitative variant (RT-qPCR) are the most sensitive and specific methods for detecting FCoV RNA in clinical samples [7, 12, 16]. These assays typically target conserved regions of the viral genome, such as the 7b gene, the N gene, or the M gene, which are present in both FECV and FIPV [7, 12, 34]. Detection of viral RNA in an effusion (abdominal or pleural fluid), cerebrospinal fluid (CSF), or tissue biopsy is considered highly supportive of FIP, as FECV is not expected to be present in these compartments in the absence of systemic infection [16, 30, 42]. Peritoneal fluid has been shown to have the highest diagnostic yield, with an odds ratio of 7.51 for FCoV detection compared to other sample types, while blood samples have a significantly lower detection rate (OR 0.08) [16]. For cats with neurological FIP, testing of CSF is valuable, with a reported sensitivity of 83.3% in one study, though detection of spike gene mutations in CSF does not appear to enhance specificity [42].

Serology: Serological assays, including immunofluorescence antibody tests (IFAT) and enzyme-linked immunosorbent assays (ELISA), detect antibodies against FCoV [9, 29, 41]. While a positive serological result confirms exposure to the virus, it cannot distinguish between FECV and FIPV infections. High antibody titers are often, but not invariably, associated with FIP, particularly the effusive form, and a negative result in a cat with clinical signs typical of FIP can sometimes be seen due to immune complex formation or the "consumptive" nature of the disease [9, 41]. The FCoVCHECK Ab ELISA, a recently developed indirect ELISA, demonstrated 93.5% sensitivity and 100% specificity compared to the reference standard IFAT, and can provide results within one hour [9]. However, serology is best used as a supportive tool rather than a definitive diagnostic test.

Rapid Point-of-Care Tests: Rapid immunochromatographic test strips (ICS) have been developed for the detection of FCoV antigen, typically targeting the highly conserved N protein [6, 8]. One such ICS, using colloidal gold nanoparticles conjugated to monoclonal antibodies, showed 98.3% agreement with RT-PCR results for detecting FCoV in clinical samples, with no cross-reactivity against other common feline viruses (feline herpesvirus, feline

Molecular Pathogenesis: Mutation-Driven Immune Dysregulation in FIP Development

The transition from a benign, enteric feline coronavirus (FCoV) infection to the fatal systemic disease known as feline infectious peritonitis (FIP) represents one of the most complex and enigmatic paradigms in viral immunopathology. This process is not a simple consequence of viral load or a single genetic event; rather, it is a multi-factorial cascade driven by specific viral mutations that fundamentally alter cellular tropism, disrupt host immune surveillance, and precipitate a catastrophic, dysregulated inflammatory response. The prevailing model, supported by decades of molecular epidemiology and, more recently, by sophisticated reverse genetics systems, posits that FIP arises from the acquisition of critical mutations in the viral genome, most notably within the spike (S) protein and accessory genes, that transform the ubiquitous, minimally pathogenic feline enteric coronavirus (FECV) into the highly virulent FIP virus (FIPV) [22, 26]. This internal mutation theory, while central, is now understood to operate within a complex interplay of host genetics, immune status, and environmental stressors, ultimately determining which infected cats will succumb to this invariably fatal disease [2, 18].

The Spike Protein: The Molecular Arbiter of Tropism and Pathogenesis

The S protein is the primary determinant of FCoV tropism and the key molecular switch governing the transition to FIP. The critical functional distinction between FECV and FIPV lies in the shift from a tropism for intestinal epithelial cells to a tropism for monocytes and macrophages [4, 27]. This shift is not a single event but a spectrum of adaptive changes, with the S1/S2 furin cleavage site (FCS) emerging as a central hotspot for mutations that correlate with systemic spread. The FCS is a polybasic amino acid motif (R-X-X-R) that is cleaved by host furin-like proteases, a process essential for viral entry. Comparative analyses of FECV and FIPV sequences have revealed that FIPV isolates exhibit a significantly higher prevalence of a minimal R-X-X-R recognition motif (41.94%) compared to FECV (9.1%), suggesting that enhanced cleavability is a key feature of the pathogenic biotype [53]. Furthermore, studies employing sophisticated molecular evolutionary statistics have identified specific sites within the S1/S2 FCS and the adjacent fusion domain that are under differential selective pressure between the two biotypes [26, 51]. Notably, a signal of relaxed selection on the FCS in FIPV relative to FECV has been observed, leading to the hypothesis that furin cleavage functionality may be altered or even dispensable for the macrophage-tropic virus, potentially allowing for alternative entry pathways [26, 51].

Beyond the FCS, specific point mutations in the S protein have been consistently associated with FIP. The most widely recognized are the M1058L and S1060A substitutions, located in the putative fusion peptide region near the S2' cleavage site [30, 49]. These mutations are highly prevalent in systemic tissues and effusions of cats with FIP but are rarely found in the feces of healthy FCoV carriers, making them a valuable, though not absolute, diagnostic marker [30, 40, 41]. The M1058L mutation, in particular, has been detected in over 94% of FIPV isolates from China, underscoring its global significance [40]. The functional consequence of these substitutions is believed to enhance the efficiency of membrane fusion, facilitating viral entry into macrophages, which are otherwise resistant to FECV infection [46, 49]. The recent emergence of a highly pathogenic FCoV-CCoV recombinant (FCoV-23) in Cyprus has further expanded our understanding of S-driven pathogenesis. This virus, responsible for a devastating epizootic, harbors a near-cat-specific deletion in the N-terminal domain 0 of the S protein, present in over 90% of FIP cases [5, 24]. This deletion, along with other amino acid changes in the receptor-binding domain, is strongly indicative of an altered receptor binding profile and a profound shift in cell tropism, likely contributing to the virus's remarkable ability to infect cats of all ages and cause direct transmission of FIP [5, 45]. Retrospective analyses of FCoV-2 cases in the USA have similarly identified within-host deletions in domain 0, supporting a model where a "long" version of spike is transmitted between cats, but a "short," deletion-containing version is generated internally during prolonged infection and is associated with rapid systemic dissemination and high pathogenicity [36].

Immune Dysregulation: From T-Cell Exhaustion to Cytokine Storm

The acquisition of macrophage tropism by FIPV is the precipitating event for a profound and ultimately fatal immune dysregulation. Unlike the controlled, cell-mediated immune response that typically contains FECV, FIPV-infected macrophages become a permissive reservoir for viral replication and a source of potent inflammatory mediators. The hallmark of FIP immunopathogenesis is a failure of the T-cell response, characterized by a progressive lymphopenia and a state of T-cell exhaustion [27, 50]. This exhaustion is molecularly defined by the upregulation of inhibitory receptors such as PD-1, TIM-3, and LAG-3 on cytotoxic T lymphocytes, rendering them incapable of clearing infected macrophages [50]. Critically, it has been demonstrated that FIPV, but not FECV, specifically upregulates the expression of PD-L1, the ligand for PD-1, on infected cells [27]. This virus-driven induction of an immune checkpoint pathway provides a direct mechanism for FIPV to actively suppress the antiviral T-cell response, creating a permissive environment for persistent systemic infection [27]. The downstream consequences of this T-cell dysfunction are catastrophic. The failure of adaptive immunity, combined with the relentless replication of FIPV in macrophages, triggers an uncontrolled, innate inflammatory response. This is manifested as a "cytokine storm," with transcriptomic analyses of mesenteric lymph nodes from FIP-affected cats revealing a massive upregulation of pro-inflammatory cytokines and chemokines, including IL-1β, IL-6, TNF-α, and CXCL10 [47, 52]. This inflammatory milieu is driven by the activation of pattern recognition receptors, particularly Toll-like receptors (TLRs) 2, 4, and 8, which recognize viral components and amplify the dysregulated signaling cascade [52]. The resulting systemic inflammation is the direct cause of the clinical hallmarks of FIP, including pyogranulomatous vasculitis, protein-rich effusions, and multi-organ failure [10, 31].

The Role of Accessory Genes and Viral Recombination

While the S protein is the primary driver of tropism, mutations in the accessory genes, particularly ORF3c and ORF7b, are also strongly implicated in FIP pathogenesis. The ORF3c gene is frequently found to be truncated or mutated in FIPV isolates, leading to a loss of function [30, 54]. This is in stark contrast to FECV, where an intact ORF3c is almost universally conserved, suggesting that the loss of this protein's function is a critical step in the emergence of the virulent biotype [30]. The precise role of ORF3c is still under investigation, but it is thought to act as an interferon antagonist, and its inactivation may paradoxically contribute to the heightened inflammatory response seen in FIP [26]. Similarly, ORF7b shows signals of relaxed selection in FIPV, with a high number of positively selected sites associated with the FECV phenotype, indicating that its function may be specifically required for enteric replication but dispensable for systemic infection [26, 51]. The emergence of FCoV-23 has also highlighted the profound impact of recombination on FIP pathogenesis. This virus is a recombinant between FCoV and canine coronavirus (CCoV), with a minor recombination region spanning the S gene that shows 96.5% identity to a pantropic canine coronavirus [5, 24]. This event has created a virus with a novel genetic architecture that bypasses the typical requirement for internal mutation, resulting in a directly transmissible, highly pathogenic FIPV that has caused a large-scale epizootic [5, 45]. This underscores the potential for recombination to create novel pathogens with unpredictable pathogenic properties, a concern that resonates with global health authorities like the World Organisation for Animal Health (WOAH) in the context of emerging coronavirus threats.

Genetic Diversity and Circulating Strains: Type I and Type II FCoV in Domestic and Wild Felids

The Genomic Dichotomy: Defining Type I and Type II Feline Coronavirus

The genetic architecture of feline coronavirus (FCoV) is predicated upon a fundamental dichotomy that has profound implications for viral evolution, host range, and pathogenesis. FCoV is classified into two distinct serotypes, Type I and Type II, primarily based on antigenic and genetic differences within the spike (S) protein, the principal determinant of viral tropism and cellular entry [33, 46]. This distinction is not merely a taxonomic convenience but reflects divergent evolutionary trajectories, with Type I FCoV representing the ancestral, “authentic” feline lineage, while Type II FCoV is a recombinant hybrid that has incorporated genetic material from canine coronavirus (CCoV) [13, 33]. The S gene of Type I FCoV shares significant homology with that of human coronavirus 229E (HCoV-229E) and HCoV-NL63, both alphacoronaviruses, whereas the Type II S gene is a product of homologous recombination between Type I FCoV and CCoV, resulting in a chimeric spike protein that confers distinct receptor-binding properties and cellular entry mechanisms [20, 46]. This recombination event, thought to have occurred historically, involved the acquisition of a large fragment spanning from open reading frame 1b (ORF1b) to the membrane (M) gene, with the minor recombinant region, the S gene itself, showing as much as 96.5% sequence identity to pantropic canine coronavirus strains such as NA/09 [5, 24]. Consequently, Type II FCoV utilizes feline aminopeptidase N (fAPN) as its primary cellular receptor, a trait shared with CCoV and several other alphacoronaviruses, while the receptor for Type I FCoV remains enigmatic, representing a critical gap in our understanding of serotype-specific biology [38, 46]. The practical implications of this genetic divergence are profound: Type II FCoV has been far more amenable to in vitro propagation, leading to a historical research bias wherein the less prevalent serotype has been disproportionately studied in cell culture systems, while the globally dominant Type I has remained comparatively refractory to laboratory manipulation [15, 38]. The recent development of culture-adapted feline cell lines, such as FCWF-4 CU, and the advent of reverse genetics systems, including circular polymerase extension reaction (CPER) methods, have begun to redress this imbalance, enabling the generation of recombinant Type I viruses and facilitating functional studies of serotype-specific genetic elements [11, 19, 38].

Global Prevalence and Geographical Distribution: The Dominance of Type I

Epidemiological surveys conducted across diverse geographical regions consistently demonstrate the overwhelming predominance of Type I FCoV in both healthy and FIP-affected feline populations. In a landmark molecular epidemiological study from China, Li et al. (2018) analyzed 126 FCoV-positive samples from clinically healthy cats and FIP-suspected cases, revealing that Type I FCoV accounted for an astonishing 95.8% (91/95) of successfully sequenced isolates, with Type II constituting a mere 4.2% (4/95) [3]. This pattern of Type I dominance is not confined to China but represents a global phenomenon, with similar ratios reported across Europe, Asia, and the Americas [33, 48]. A comprehensive review of the emerging landscape of FCoV Type II in Asia corroborates these findings, emphasizing that while Type I remains the predominant serotype throughout the continent, Type II is detected at considerably lower frequencies, though its distinct molecular characteristics, including unique recombination breakpoints within the S gene and variations in accessory genes such as 3c, warrant continued surveillance [33]. The preponderance of Type I strains in natural infections raises fundamental questions about the selective pressures that maintain this distribution. It has been hypothesized that Type I FCoV may possess superior transmission fitness in multi-cat environments, possibly due to enhanced stability in the fecal-oral route or more efficient replication within the gastrointestinal epithelium, the primary site of FECV replication [23, 46]. Alternatively, the historical recombination event that generated Type II may have conferred a fitness cost under most ecological conditions, with Type II only achieving epidemiological relevance under specific circumstances, such as in certain geographic regions or during outbreak scenarios [5, 24]. Notably, the recent emergence of a highly pathogenic FCoV-CCoV recombinant (FCoV-23) in Cyprus, which caused a rapidly spreading FIP epizootic, demonstrates that Type II variants can achieve high prevalence and pathogenicity under the right conditions, challenging the notion that Type II is intrinsically less fit [5, 24, 45]. This outbreak, originating in Cyprus and characterized by a domain 0 deletion in the S protein present in over 90% of FIP cases, underscores the dynamic nature of FCoV genetic diversity and the potential for novel recombinants to emerge and spread rapidly, infecting cats of all ages and causing high mortality [5, 24].

Genetic Diversity Within Type I FCoV: Novel Clades and Emerging Variants

The genetic landscape of Type I FCoV is far from monolithic; rather, it is characterized by substantial heterogeneity, with multiple clades and sub-lineages circulating both regionally and globally. Phylogenetic analyses of partial S gene sequences from Chinese isolates have revealed that the 91 Type I strains examined exhibited considerable genetic diversity, clustering into distinct clades, with three strains, HLJ/HRB/2016/10, HLJ/HRB/2016/11, and HLJ/HRB/2016/13, forming a potential new clade in nearly complete genome-based phylogenetic trees [3]. This finding suggests that the evolutionary dynamics of Type I FCoV are ongoing, with novel lineages continually arising, potentially through accumulation of point mutations, recombination, or both. The complete genome sequencing of the Japanese strain FIPV-Aqua and the Chinese isolate HL2019 has further expanded our understanding of Type I genomic architecture [20, 55]. Strain HL2019, isolated and characterized from mainland China, was shown to be a recombinant of two existing Type I strains, China/ZJU1709 and Netherlands/UU16, demonstrating that recombination is not a phenomenon exclusive to the generation of Type II but also occurs within Type I lineages, contributing to their genetic plasticity [20]. This intra-serotype recombination may serve as a mechanism for the generation of novel pathogenic variants, as evidenced by the ability of HL2019 to induce severe clinical signs and mortality in experimentally infected cats [20]. Furthermore, the identification of specific genetic markers within the S gene of Type I strains has provided insights into the molecular correlates of pathogenicity. The M1058L mutation in the S protein, which has been strongly associated with the development of FIP, was detected in 94.68% (89/94) of FIP-associated Type I isolates from China, underscoring the central role of this residue in the biotype switch from benign FECV to virulent FIPV [40]. Conversely, the presence of a six-nucleotide deletion (C4035-AGCTC4040) in the S gene of three Type I strains from China, BJ/2017/27, BJ/2018/22, and XM/2018/04, highlights the potential for insertions and deletions (indels) to shape viral phenotype, though the functional consequences of this particular deletion remain to be fully elucidated [3]. The advent of high-throughput sequencing technologies, including hybridization capture and next-generation sequencing, has revolutionized our ability to characterize Type I genomes from clinical samples, overcoming previous technical challenges associated with the low viral loads and genetic variability of this serotype [13]. This methodological advancement has been instrumental in demonstrating, for the first time, the cross-species transmission of Type I FCoV between domestic cats and wild felids, extending the known host range of this serotype and highlighting the importance of genomic surveillance in both domestic and captive populations [13].

Type II FCoV: Recombination, Deletion Mutants, and the Cyprus Epizootic

While Type II FCoV is less prevalent globally, its capacity for generating highly pathogenic variants through recombination with CCoV makes it a subject of intense investigation and concern. The recent emergence of FCoV-23 in Cyprus represents a watershed moment in FCoV research, as this novel recombinant strain was responsible for a large-scale, rapidly spreading FIP epizootic that infected cats of all ages, a departure from the typical demographic pattern where FIP predominantly affects young kittens [5, 24, 45]. Whole-genome sequencing of FCoV-23 revealed a complex recombinatorial architecture: the minor recombinant region, spanning the S gene, showed 96.5% sequence identity to the pantropic canine coronavirus NA/09, while other regions of the genome retained typical FCoV ancestry [5, 24]. This genetic chimerism likely underpins the enhanced pathogenicity and altered transmission dynamics observed during the outbreak. Critically, a near-cat-specific deletion in domain 0 of the S protein, the N-terminal domain involved in initial attachment, was present in more than 90% of FIP cases from the Cyprus epizootic, providing compelling evidence that this deletion is functionally linked to the emergence of the highly pathogenic phenotype [5, 24]. The domain 0 deletion, along with several amino acid changes in the receptor-binding domain (RBD), suggests potential alterations in receptor binding and cell tropism, possibly facilitating a shift from the enteric to the systemic compartment [5, 24, 36]. Retrospective analysis of Type II FCoV cases from the United States has further elucidated the role of within-host deletions in the pathogenesis of this serotype. Olarte-Castillo et al. (2026) characterized three FIP cases caused by FCoV-2, two of which, cats 344 and 597, exhibited prolonged clinical signs lasting at least two months and were found to harbor distinct deletions in domain 0 of the S gene, which were present in all examined tissues [36]. In contrast, cat 346, the short-term infected daughter of cat 344, harbored an intact (or “long”) spike gene, consistent with a model in which the long version of spike is transmitted between cats, while the short version, containing the domain 0 deletion, is generated de novo within each cat following prolonged infection and subsequently spreads systemically [36]. This “internal deletion” model posits that the high pathogenicity of FCoV-2 is associated with the acquisition of deletions in the S gene during within-host evolution, rather than being an inherent property of the transmitted virus. The finding that low RNA titers of the short-spike variant were detected in feces suggests that while these deletion mutants are highly pathogenic in the systemic compartment, they may be inefficiently shed, limiting their transmission potential and necessitating the continued circulation of the long-spike form within populations [36].

FCoV in Wild Felids: Host Range, Conservation Implications, and Cross-Species Transmission

FCoV is not restricted to domestic cats (Felis catus) but poses a significant threat to nondomestic felid species, many of which are already vulnerable or endangered. The susceptibility of wild felids to FCoV infection and FIP has been documented across a diverse range of species, including cheetahs (Acinonyx jubatus), European wildcats (Felis silvestris), tigers (Panthera tigris), mountain lions (Puma concolor), lions (Panthera leo), and Pallas’ cats (Otocolobus manul) [14, 39]. The consequences of FCoV introduction into naïve wild felid populations can be devastating, as exemplified by a notable outbreak in a cheetah collection where the virus caused widespread mortality [14]. This outbreak underscores the principle that FCoV, while ubiquitous and often innocuous in domestic cat populations, can act as a primary pathogen in immunologically naïve or genetically homogenous groups. The molecular characterization of FCoV from wild felids has historically been hampered by technical challenges related to the high genetic variability of the S gene and the limited availability of samples. However, the application of hybridization capture and next-generation sequencing has enabled the first definitive demonstration of cross-species transmission of Type I FCoV between a domestic cat and a captive wild felid, a Pallas’ cat sharing the same room in a zoological institution [13]. This study provided unequivocal genomic evidence that the same Type I FCoV strain infected both animals, confirming that domestic cats can serve as a source of infection for captive wild felids and highlighting the need for stringent biosecurity measures in zoological settings to prevent spillover events [13]. The prevalence of FCoV in captive nondomestic felids varies considerably by facility and species. In a survey of three zoological institutions in Northern Italy, Ratti et al. (2022) reported an overall FCoV prevalence of 7.9% (3/38 animals), with infection detected in tiger cubs from the same litter, suggesting horizontal transmission within the captive environment [39]. The detection of FCoV in oral swabs from these cubs raises the possibility of alternative transmission routes beyond the fecal-oral pathway, which may be particularly relevant in settings where animals engage in communal feeding or grooming [39]. The first confirmed case of FIP in a Persian leopard (Panthera pardus tulliana), a critically endangered subspecies, further illustrates the conservation threat posed by FCoV [10]. Molecular diagnostics targeting the FCoV M gene confirmed infection in a captive leopard that succumbed to effusive FIP, with postmortem examination revealing characteristic pyogranulomatous inflammation, vasculitis, and effusive fluid accumulation [10]. This case serves as a sentinel event, signaling that FCoV is an emerging pathogen for endangered felids and that enhanced surveillance and preventive measures, including vaccination, if available, and strict quarantine protocols, are urgently needed to protect captive populations [10, 14]. The World Organisation for Animal Health (WOAH) recognizes FCoV as a pathogen of domestic cats, but its impact on wild felid conservation falls within the broader framework of the “One Health” approach, which acknowledges the interconnectedness of human, animal, and environmental health [10, 28].

Evolutionary Pressures and the Genetic Basis of Pathogenicity

The transition from benign FECV to virulent FIPV is not driven by a single “switch” mutation but rather by a complex interplay of multiple genetic alterations across the viral genome, subject to differential selective pressures. State-of-the-art molecular evolutionary analyses, employing techniques to detect variations in natural selection pressure between FECV and FIPV sequences, have identified key sites within the spike protein that are under positive selection in FIPV. Zehr et al. (2023) analyzed full-length FCoV protein-coding genes, including spike, ORF3abc, and ORF7ab, and identified two sites exhibiting significant differences in selection pressure between the two biotypes: one within the S1/S2 furin cleavage

Epidemiology: Prevalence, Transmission Dynamics, and Risk Factors in Multi-Cat Environments

The epidemiology of feline coronavirus (FCoV) is characterized by its near-ubiquitous distribution within multi-cat environments, a complex transmission ecology dominated by fecal-oral pathways, and a constellation of host, viral, and environmental risk factors that collectively determine whether infection remains benign or progresses to the fatal disease feline infectious peritonitis (FIP). Understanding these epidemiological parameters is not merely an academic exercise; it is the foundation upon which effective control strategies, diagnostic algorithms, and preventive interventions are built. In multi-cat households, shelters, breeding catteries, and zoological collections, the dynamics of FCoV transmission create an environment where the virus is nearly impossible to eradicate, and where the sporadic emergence of pathogenic mutants poses a persistent threat.

Prevalence in Multi-Cat Environments: A Spectrum of Seropositivity and Viral Shedding

FCoV is among the most prevalent viral pathogens of domestic cats, with infection rates that vary dramatically according to population density and management practices. In solitary household cats, seroprevalence typically ranges from 20% to 60%, reflecting the relatively lower probability of exposure to infected conspecifics [17]. However, in multi-cat environments, these figures escalate sharply. Studies consistently report that virtually all cats in crowded breeding catteries and shelters become infected at some point, with seroprevalence approaching 90–100% in endemic populations [1, 2, 23]. A comprehensive Greek serosurvey of 453 cats found an overall seroprevalence of 12.1%, but this figure was heavily influenced by population type: cats adopted as strays and those with reported contact with other cats were significantly more likely to be seropositive, underscoring the profound impact of social structure on transmission risk [29].

The prevalence of active viral shedding, detected by reverse transcription quantitative PCR (RT-qPCR) targeting conserved genes such as the nucleocapsid (N) or membrane (M) genes, often exceeds seroprevalence in high-density settings because many cats are chronic shedders. In a large-scale US study analyzing 14,035 clinical samples, FCoV detection rates were highest in young cats aged 0–1 year and in purebred cats, particularly British Shorthairs, who exhibited an odds ratio of 2.81 for infection compared to mixed-breed cats [16]. Similarly, a Chinese investigation of 169 cats from veterinary hospitals detected FCoV RNA in 74.6% of samples, with 75.7% positivity among FIP-suspected cases and 72.2% among clinically healthy cats [3]. The near-identical detection rates between symptomatic and asymptomatic groups highlight a critical epidemiological reality: the vast majority of FCoV-infected cats are clinically healthy carriers who nonetheless actively shed virus into the environment.

Regional variations in FCoV seroprevalence are striking. The UK domestic cat population shows an overall FCoV-II neutralizing antibody seroprevalence of 13.6%, but total seroprevalence rises to 59.5% when all antibody isotypes are considered [32]. In contrast, seroprevalence in Greek cats was only 12.1% [29], while in Turkey, a separate study of stray cats reported much higher rates [1]. These disparities likely reflect differences in population density, husbandry practices, and the prevalence of multi-cat housing rather than true geographic variation in viral virulence. The recent emergence of a highly pathogenic FCoV-CCoV recombinant in Cyprus (FCoV-23) has introduced a new epidemiological dimension, with infection spreading rapidly across the island and infecting cats of all ages, with a mean age of affected cats of 3.9 years, considerably older than the typical FIP demographic [5, 24, 45]. This outbreak strain has demonstrated a capacity for direct transmission of the pathogenic biotype, challenging the long-held dogma that FCoV is transmitted exclusively as the benign enteric form.

Transmission Dynamics: The Fecal-Oral Highway and the Role of Fomites

FCoV transmission is overwhelmingly driven by the fecal-oral route, with infected cats shedding large quantities of virus in their feces, often for months or years [2, 18, 23]. The primary vector for transmission is the contaminated litter box. In multi-cat households where multiple cats share a single litter box or where boxes are not cleaned frequently enough, the virus circulates continuously. Indeed, the risk of FCoV infection is directly proportional to the number of cats in a household and the degree of litter box sharing [18, 23]. Indirect transmission via fomites, including contaminated bedding, food bowls, grooming tools, and even the hands and clothing of caretakers, is considered the most common route of spread, as the virus can persist in the environment for weeks under appropriate conditions of moisture and temperature [18].

Shedding patterns are highly variable among individuals. Some cats are high-level persistent shedders, excreting viral RNA at concentrations that ensure efficient transmission to naïve housemates. Others shed intermittently or at low levels, while a small proportion of cats appear to be resistant to infection or clear the virus rapidly [25, 44]. Mathematical modeling using susceptible-infected-susceptible (SIS) frameworks has demonstrated that FCoV can maintain an endemic equilibrium in multi-cat populations, with the virus persisting indefinitely as long as there is a continuous supply of susceptible kittens or newly introduced adults [1]. The model predicts that the prevalence of FCoV infection will always dominate over FIP within a population, consistent with empirical observations that FIP occurs in only 5–12% of infected cats [1, 2, 18].

The critical role of environmental contamination is underscored by intervention studies showing that rigorous hygiene protocols, including the use of separate litter boxes for each cat, daily removal of feces, and disinfection with bleach or other coronavirucidal agents, can dramatically reduce transmission. In one landmark study, the elimination of FCoV fecal shedding through a short course of oral GS-441524 prevented FIP in all 147 treated cats from 27 households, with a follow-up period of up to 3.5 years [25]. This intervention effectively broke the transmission cycle within these multi-cat environments, demonstrating that FCoV dynamics are driven by continuous re-exposure rather than by persistent latent infection.

Interestingly, recent evidence suggests that direct transmission of the pathogenic FIP biotype may be possible under certain circumstances. The Cyprus epizootic, where sequence identities of samples from cats in different districts strongly supported direct transmission of FCoV-23, represents a paradigm shift [5, 24]. Furthermore, a retrospective analysis of a shelter outbreak in the USA documented three cats that concurrently developed FIP after sharing an environment, with molecular analysis of the spike gene revealing varied amino acid alterations both between cats and between sample types within individual cats [56]. This pattern supports a "circulating virulent-avirulent theory," wherein mildly pathogenic FCoV variants can circulate within a population and, under appropriate selective pressures, undergo mutations that lead to FIP in multiple cats simultaneously.

Risk Factors: The Interplay of Host, Virus, and Environment

The development of FIP following FCoV infection is a multifactorial process, and the identification of specific risk factors has been a major focus of epidemiological research. These factors can be broadly categorized into host-related, virus-related, and environment-related influences.

Host Age and Breed. Age is one of the most consistently identified risk factors for both FCoV infection and FIP. Kittens and young adult cats under two years of age are at the highest risk. Multiple large-scale studies have found that cats aged 0–1 year have significantly higher FCoV detection rates compared to older cats [3, 16, 40]. A Chinese study reported that FCoV infection was significantly correlated with age (p < 0.01), with cats under six months being particularly vulnerable [3]. Similarly, in the UK, most studies report that approximately 70% of FIP cases occur in purebred cats under two years of age [18]. This age predisposition likely reflects the waning of maternally derived antibodies combined with an immature immune system that is less capable of containing viral replication. Purebred cats are overrepresented in FIP case series, with British Shorthairs, Persians, and other pedigree breeds showing elevated odds ratios [16, 18]. This may be due to genetic predisposition, but also to the intensive breeding practices and high population densities typical of catteries.

Multi-Cat Housing and Environmental Stress. The single most important environmental risk factor for FCoV infection is living in a multi-cat environment. The odds of FCoV seropositivity increase with each additional cat in the household [29]. Shelters, breeding catteries, and rescue facilities are hotspots for FCoV transmission because they combine high population density, constant introduction of new cats, and stress-induced immunosuppression [2, 23]. The stress of overcrowding, poor nutrition, concurrent illness, and the social disruption of rehoming all contribute to increased viral shedding and heightened susceptibility to FIP. In the Cyprus epizootic, affected cats were older (mean 3.9 years) than typical FIP cases, and neurological manifestations were significantly more common, suggesting that the novel recombinant virus may have different age-related risk profiles [5, 45].

Viral Genetics and Mutation. The transition from benign FECV to pathogenic FIPV is driven by the accumulation of specific mutations, particularly in the spike (S) gene. The M1058L mutation in the S protein is strongly associated with FIP and is found in a high proportion of systemic samples from FIP cases [30, 40, 49]. In a Chinese study of 120 ascitic fluid samples from FIP-suspected cats, 94.68% harbored the M1058L mutation [40]. The S1060A mutation is also frequently detected [30, 49]. Importantly, these mutations are rarely found in fecal samples from healthy carrier cats, suggesting that they arise de novo within the infected host during the course of prolonged enteric infection [30, 37]. The S1/S2 furin cleavage site is another hotspot for mutation, and variation at this site has been linked to altered cellular tropism and pathogenicity [26, 56]. The recent identification of a six-nucleotide deletion in domain 0 of the S gene in FCoV-23, present in more than 90% of FIP cases in Cyprus, further supports the idea that specific genetic signatures can increase transmissibility and virulence of the biotype [5, 24, 36].

Host Immune Status and Genetic Background. The host immune response is the ultimate arbiter of whether FCoV infection remains harmless or progresses to FIP. Cats that develop FIP typically mount a strong but ineffective humoral response, characterized by high antibody titers that paradoxically exacerbate disease through antibody-dependent enhancement (ADE) [27, 57]. In contrast, cats that resist FIP develop a robust cell-mediated immune response with strong cytotoxic T-lymphocyte activity. A whole-transcriptome analysis of mesenteric lymph nodes revealed that FIP is associated with downregulation of T-cell-related processes and upregulation of pro-inflammatory pathways, whereas non-FIP FCoV-positive cats showed enrichment of antiviral defenses without the pathological inflammation [47]. The programmed cell death protein 1 (PD-1)/PD-L1 immune checkpoint axis appears to play a critical role: FIPV infection, but not FECV infection, upregulates PD-L1 expression on infected macrophages, leading to T-cell exhaustion and impaired viral clearance [27]. Mesenchymal stem cell therapy has been shown to reverse this exhaustion and promote immune recovery in treated cats [50]. Genetic factors are also likely important, as certain pedigrees are overrepresented in FIP case series, even when controlling for environmental exposure [16, 18].

Coinfections and Concurrent Disease. Infection with feline immunodeficiency virus (FIV) or feline leukemia virus (FeLV) has been proposed as a risk factor for FIP, as these immunosuppressive viruses could impair the host's ability to control FCoV replication. However, epidemiological data are conflicting. A Chinese study of 120 FIP-suspected cats found no FIV infections and only one FeLV infection (0.92%), suggesting that retroviral coinfection is not a prerequisite for FIP [40]. In contrast, a Turkish serosurvey reported that 12.5% of FCoV-seropositive cats also had FIV antibodies, and 3.9% were positive for FeLV antigen, but the clinical significance of these coinfections remains unclear [28].

Implications for Disease Control in Multi-Cat Settings

The epidemiological patterns described above have direct implications for the management of FCoV in multi-cat environments. The high prevalence and prolonged shedding mean that eradication is rarely feasible without aggressive intervention. However, breaking the transmission cycle through strict hygiene, segregation of shedding cats, and, increasingly, through the strategic use of antivirals to eliminate shedding has proven remarkably effective at preventing FIP [25, 44]. The identification of high-risk groups (kittens, purebreds, cats in high-density housing) allows for targeted surveillance and early intervention. The recognition that viral mutations accumulate during prolonged enteric infection underscores the importance of reducing viral load and shortening the duration of shedding through environmental management and, where appropriate, antiviral therapy. Finally, the emergence of recombinant FCoV-23 with direct transmissibility of the pathogenic biotype serves as a stark reminder that FCoV epidemiology is not static; ongoing genomic surveillance is essential to detect novel variants with altered transmission dynamics or virulence [5, 24].

Clinical Manifestations: Effusive and Non-Effusive Forms of FIP and Disease Progression

Feline infectious peritonitis (FIP) represents the culmination of a complex, and often stochastic, pathogenic process wherein a ubiquitous, ordinarily benign enteric pathogen, feline coronavirus (FCoV), acquires the capacity for systemic macrophage tropism and triggers a devastating, immune-mediated systemic disease [2, 22]. The clinical presentation of FIP is notoriously pleomorphic, a reflection of the underlying interplay between viral virulence determinants, the magnitude and anatomical distribution of the ensuing pyogranulomatous inflammatory response, and the specific nature of the host’s immune response. Historically, the disease has been dichotomized into two principal clinical phenotypes: the effusive (or “wet”) form and the non-effusive (or “dry”) form. However, it is critical to recognize that these are not discrete, immutable entities but rather represent poles on a continuous clinical spectrum; a substantial proportion of affected cats will exhibit features of both forms simultaneously or will transition from one phenotype to another over the course of their illness [22, 23]. The immunopathologic basis for this phenotypic variation lies in the character and efficacy of the cell-mediated immune (CMI) response. A robust and effective CMI response tends to contain the viral infection within discrete foci of pyogranulomatous inflammation, yielding the non-effusive form, whereas a weak or absent CMI response, paradoxically accompanied by a strong, non-protective humoral response, permits unchecked viral replication and widespread immune complex deposition, culminating in the vasculitis and effusions that define the effusive form [22, 47, 52]. The emergence of novel, highly pathogenic recombinant strains, such as FCoV-23 associated with the Cypriot epizootic, has further complicated this clinical picture, with reports of altered age predilection and an increased frequency of neurological involvement [5, 24, 45].

The Effusive (Wet) Form: Pathophysiology of Systemic Vasculitis and Cavitary Effusions

The effusive form of FIP is typically the more acute and rapidly progressive manifestation of the disease, often running a clinical course of days to a few weeks from the onset of noticeable signs to a terminal outcome. The hallmark of this form is the development of protein-rich, fibrinous effusions within body cavities, resulting from a severe, systemic pyogranulomatous vasculitis [10, 54]. The fundamental pathogenic lesion is a perivascular inflammatory infiltrate centered on venules and small arteries, particularly within the serosal surfaces of the abdominal and thoracic cavities, the omentum, and the meninges. This vasculitis is driven by the deposition of circulating FCoV-antibody immune complexes within the vascular endothelium, leading to complement activation, neutrophil chemotaxis, and increased vascular permeability [22, 47]. The resulting effusion is characteristically a sterile, viscous, straw-yellow to amber-colored fluid that may contain fibrin strands or clots. Analysis of this fluid reveals a high specific gravity (typically >1.017) and a high protein content (often >35 g/L), consistent with an exudate. The total nucleated cell count is variable but is often moderately elevated, with a cytological picture dominated by macrophages and neutrophils, a pyogranulomatous exudate [60, 61]. The Rivalta test, a simple qualitative test for the detection of high protein and inflammatory mediators in the fluid, is frequently positive in these cases and has historically been used as a supportive diagnostic tool, though it lacks specificity [28, 61].

Clinically, the most conspicuous finding in cats with the effusive form is abdominal distension due to the accumulation of ascitic fluid [7, 28, 31]. This is often accompanied by a palpable “fluid wave” and a distinct dull sound upon abdominal percussion. In a subset of cats, the effusion is primarily thoracic (pleural effusion), leading to a restrictive breathing pattern, tachypnea, dyspnea, and muffled heart and lung sounds on auscultation [31, 59]. These cats often exhibit an orthopneic posture, refusing to lie down. Concurrent pericardial effusion can occur, but it is rarely of sufficient volume to cause hemodynamic compromise (cardiac tamponade) in isolation. Beyond the effusions, cats with wet FIP are profoundly systemically ill. They present with a chronic, non-responsive fever (often of ≥39.5°C) that is unresponsive to broad-spectrum antibiotics, profound lethargy and anorexia, and rapid weight loss and muscle wasting [28, 45, 56]. Icterus is a common and often striking finding, resulting from a combination of hepatic involvement, hemolysis, and cholestasis [56, 61]. Less consistent but notable findings include diarrhea, vomiting, and, in some cases, palpable abdominal masses representing matted omentum and pyogranulomatous lymphadenopathy [7, 60].

Hematological and serum biochemical abnormalities are non-specific but provide strong supportive evidence of severe systemic inflammation and organ dysfunction. Common findings include a normocytic, normochromic anemia, often of a non-regenerative nature, and a leukocytosis characterized by neutrophilia (with or without a left shift) and lymphopenia [31, 60]. Serum biochemistry frequently reveals hyperglobulinemia (primarily due to an increase in γ-globulins), a decreased albumin-to-globulin (A:G) ratio (often <0.8, and in severe cases <0.4), hyperbilirubinemia, and elevations in hepatic enzymes such as alanine aminotransferase (ALT) and aspartate aminotransferase (AST) [31, 45, 61]. Hypoalbuminemia is also a frequent finding, contributing to the decreased A:G ratio [61]. The composition of the effusion itself, high protein, low cell count with a predominance of macrophages, remains a cornerstone of antemortem diagnosis, often in concert with molecular detection of FCoV RNA via RT-PCR [7, 12, 41, 60]. Advanced diagnostics have turned to accurate quantification of viral RNA; studies utilizing quantitative RT-PCR on effusion samples demonstrate extremely high sensitivity and are considered the gold standard for confirming the presence of the virus in these fluids [16, 34].

The Non-Effusive (Dry) Form: Pyogranulomatous Inflammation without Cavitary Fluid

The non-effusive form of FIP represents a more chronic, insidious disease process, typically evolving over weeks to months. The fundamental lesion is the same, pyogranulomatous inflammation, but in this form, the inflammation is more localized and contained, resulting in the formation of discrete granulomas and areas of tissue necrosis within parenchymal organs, rather than the diffuse vasculitis and effusion seen in the wet form [54]. This occurs when a partial, but ultimately ineffective, CMI response is mounted. The host is able to contain viral spread to some degree, preventing the massive systemic immune complex deposition required for widespread vascular leakage, but is unable to achieve viral clearance [47]. Consequently, viral replication and the associated inflammatory response become focused within specific tissues.

Because the lesions are focal or multifocal, the clinical signs are directly referable to the organ system(s) involved. This makes the dry form notoriously difficult to diagnose, as the presenting signs can mimic many other diseases. The most frequently targeted organ systems include the eyes, the central nervous system (CNS), the kidneys, the liver, the pancreas, and the lymph nodes [42, 47, 49].

Ocular involvement is a hallmark of the non-effusive form and is estimated to occur in a significant proportion of cases [28, 49]. The classic presentation is a bilateral, granulomatous uveitis (anterior uveitis, posterior uveitis, or panuveitis). Clinical signs include conjunctival hyperemia, corneal edema (keratic precipitates), anisocoria, a miotic pupil that does not respond well to light, a hazy or cloudy appearance to the aqueous humor (aqueous flare), and the presence of fibrinous exudate or hyphema in the anterior chamber. On fundic examination, one may observe chorioretinitis, retinal edema, retinal hemorrhages, and perivascular cuffing ("candle-wax drippings"). The presence of bilateral uveitis in a young cat is a strong clinical indicator of FIP [49].

Neurological involvement is a particularly devastating and diagnostically challenging manifestation. While it can occur in isolation, it is frequently seen in combination with ocular or other organ involvement [42, 45]. The hallmark is a progressive, multifocal CNS disease, reflecting the presence of scattered pyogranulomas within the brain parenchyma, meninges, and spinal cord. A recent epizootic in Cyprus, caused by the recombinant FCoV-23 strain, was notable for a high incidence of neurological signs, suggesting that specific viral strains may have enhanced neurotropism [5, 45]. Common neurological signs include:

• Cerebral/Cortical Signs: altered mentation (depression, stupor, dementia), seizures, and behavioral changes.
• Brainstem/Cerebellar Signs: head tilt, nystagmus (often positional), ataxia, and cranial nerve deficits (e.g., facial paralysis, anisocoria).
• Spinal Cord Signs: ataxia, proprioceptive deficits, paresis (often pelvic limb), and urinary or fecal incontinence.
• Neuromuscular Signs: generalized weakness, muscle tremors, and hyperesthesia.

Diagnosis of neurological FIP is especially reliant on advanced diagnostics. Analyzing cerebrospinal fluid (CSF) for FCoV RNA via RT-qPCR is highly sensitive for cats with neurological involvement, with reported sensitivity exceeding 80% in some studies, whereas it is far less sensitive in cats without neurological signs [42]. The detection of spike gene mutations in CSF has not yet proven to enhance specificity [42].

Other common organ manifestations include renal involvement, which can present as renomegaly, irregular renal contours, and progressive renal failure resulting from pyogranulomatous nephritis [16, 47]. Hepatic involvement leads to hepatomegaly, icterus, and elevations in liver enzymes. Pancreatic involvement can present as pancreatitis, with associated vomiting, abdominal pain, and anorexia. Mesenteric lymphadenopathy is a very consistent finding, often detectable on abdominal palpation or ultrasound, and the mesenteric lymph nodes are believed to be a key site for the initial systemic spread of the virus after its translocation from the intestinal tract [47, 52]. It is not uncommon for a cat to present with a combination of these signs, for example, a cat with ocular uveitis, pelvic limb paresis, and hepatomegaly.

Disease Progression: From FECV to FIPV and the Transition Between Forms

The pathogenesis of FIP is best understood as a multistep process. The inciting event is infection with the ubiquitous, enteric form of the virus, feline enteric coronavirus (FECV), which typically resides within the intestinal epithelium [22, 46]. The transition from a benign enteric infection to the deadly systemic disease FIP is thought to require a key molecular event: the acquisition of mutations within the viral genome that confer the ability to infect monocytes and macrophages (a shift in cellular tropism) [4, 26, 46]. This shift from an enterocyte-tropic virus (FECV) to a macrophage-tropic virus (FIPV) is the critical gateway to systemic dissemination. While the precise mutations remain an area of intense research, mutations within the spike (S) protein are considered paramount. Specifically, mutations affecting the S1/S2 furin cleavage site (FCS) and the fusion domain, and particularly the M1058L and S1060A amino acid changes, are strongly associated with the FIPV biotype and are believed to enhance the virus’s ability to fuse with the macrophage membrane [26, 30, 40, 49, 53]. Additional mutations within the accessory genes 3c and 7b are also frequently observed in FIPV strains but are not uniformly present, suggesting that FIP pathogenesis is polygenic and not dependent on a single "switch" [26, 30, 51]. The "internal mutation theory" suggests these mutations arise de novo within an individual cat during the course of persistent FECV infection [22, 36, 46]. However, the recent Cypriot outbreak of FCoV-23, a virulent FCoV-canine coronavirus (CCoV) recombinant that appears capable of direct cat-to-cat transmission of FIP, challenges this paradigm and suggests that some virulent strains can be circulating and directly transmitted, bypassing the need for de novo internal mutation in each host [5, 24].

Once the FIPV biotype is established and circulating within the macrophage-monocyte cell lineage, the progression to clinical disease is dictated by the host’s immune response [21, 47]. As noted, a robust but ultimately ineffective humoral response contributes to the pathogenesis of the wet form via immune complex formation. Conversely, a partial CMI response leads to granuloma formation and the dry form [22, 47]. It is crucial to understand that the two forms are not static. A cat initially presenting with the effusive form, if it survives long enough, can develop the characteristic parenchymal granulomas of the dry form as the CMI response attempts to contain the infection. Conversely, a cat with the dry form can suddenly decompensate and develop effusions if the immune system’s ability to compartmentalize the virus is overwhelmed, a phenomenon often observed in the terminal stages of the disease [22]. This transition between forms underscores the dynamic and precarious nature of the host-virus equilibrium in FIP. The immune system’s failure, often characterized by T-cell exhaustion and upregulation of immune checkpoint molecules like PD-L1, allows for unchecked viral replication and is a key driver of disease progression toward the more severe, effusive phenotype [27, 50]. The end stage of both forms is inevitably a systemic, pyogranulomatous inflammation leading to multiple organ dysfunction syndrome and death, unless aggressive antiviral therapy is instituted [37, 58, 62].

Diagnostic Approaches: From Molecular Testing to Machine Learning-Based Predictive Models

The diagnosis of feline coronavirus (FCoV) infection and, more critically, the antemortem identification of feline infectious peritonitis (FIP) represents one of the most formidable challenges in contemporary veterinary medicine. The ubiquitous nature of FCoV in multi-cat environments, coupled with the fact that only a minority of infected cats (approximately 5–12%) progress to the fatal systemic disease [2, 18], creates a profound diagnostic dilemma. As Dunbar (2025) aptly frames it, FIP diagnosis is an "enigma" [2], requiring the clinician to distinguish between a benign enteric infection and a lethal, immune-mediated vasculitis. The diagnostic landscape has evolved dramatically over the past decade, transitioning from reliance on non-specific clinicopathological markers and histopathology to a sophisticated armamentarium that includes highly sensitive molecular assays, rapid point-of-care immunochromatographic devices, isothermal amplification technologies, and, most recently, the application of machine learning-based predictive models. This section provides an exhaustive examination of these diagnostic approaches, analyzing their mechanistic underpinnings, clinical utility, limitations, and the emerging role of computational analytics in transforming FIP diagnostics.

Molecular Detection: The Cornerstone of Antemortem Diagnosis

The detection of FCoV nucleic acid has become the gold standard for confirming infection, yet the interpretation of a positive result must be carefully contextualized. Reverse transcription polymerase chain reaction (RT-PCR) and its quantitative variant (RT-qPCR) are the most widely employed molecular techniques, targeting conserved regions of the viral genome, most commonly the nucleocapsid (N) gene, the membrane (M) gene, or the 7b gene [7, 12, 42]. The choice of target gene significantly influences diagnostic performance. Kopduang and colleagues (2025) conducted a comprehensive comparative study of novel primers targeting the M gene, demonstrating that RT-qPCR achieved a sensitivity of 93.75% with a detection limit of 9.14 × 10¹ copies/µL, outperforming nested RT-PCR (87.50% sensitivity, 9.14 × 10⁴ copies/µL) and conventional RT-PCR (61.25% sensitivity, 9.14 × 10⁶ copies/µL) [12]. All three assays exhibited 100% specificity against other feline viral pathogens, underscoring the reliability of M gene-targeted approaches [12].

The selection of clinical specimen is paramount to diagnostic accuracy. A landmark nationwide study by Barua et al. (2024), analyzing 14,035 clinical samples across the United States, provided robust statistical evidence that peritoneal fluid exhibits the highest odds ratio for FCoV detection (OR: 7.51; P < .001), while blood samples demonstrate significantly lower detection rates (OR: 0.08; P < .001) [16]. This finding aligns with the pathobiology of FIP, wherein the virus replicates within macrophages and monocytes in the peritoneal cavity, leading to high viral loads in effusions. The study further identified that urine, kidney, and lymph node samples yield relatively high detection frequencies, suggesting that these specimens may be underutilized in clinical practice [16]. Amalia et al. (2025) corroborated these findings in a cohort of 45 clinically suspected cats from Indonesia, reporting 100% detection in ascitic fluid versus only 45.2% in blood samples [7]. The implications are clear: when effusion is present, it should be the specimen of choice for molecular testing.

The advent of direct RT-qPCR systems, such as the PicoGene PCR1100 platform, represents a significant technological advancement for point-of-care diagnostics. Doki et al. (2026) evaluated this system, which eliminates the RNA extraction step and delivers results within approximately 40 minutes, achieving a detection limit of 150 copies/reaction with 95.5% sensitivity and 100% specificity in effusion samples [34]. This rapid turnaround time is clinically critical, as early therapeutic intervention with antiviral agents such as GS-441524 has been shown to dramatically improve outcomes [25, 37]. The ability to obtain a molecular confirmation within the timeframe of a single veterinary consultation could revolutionize the management of suspected FIP cases.

Isothermal Amplification: Bridging the Gap Between Speed and Accessibility

While RT-qPCR remains the reference standard, its requirement for expensive thermal cycling equipment and technical expertise limits its deployment in resource-constrained settings. Loop-mediated isothermal amplification (LAMP) has emerged as a compelling alternative, offering rapid amplification at a constant temperature with visual readout. Khumtong et al. (2025) developed a colorimetric RT-LAMP assay incorporating xylenol orange (XO) as a pH-dependent indicator, targeting the N gene [63]. The assay operates at 65°C for 60 minutes and exhibits high specificity for FCoV with no cross-reactivity against feline herpesvirus, feline parvovirus, or feline calicivirus. Although the detection limit (1.7 × 10¹ copies/µL) was an order of magnitude higher than qPCR, the method offers distinct advantages in simplicity and speed [63]. Rapichai et al. (2022) independently developed a neutral red-based RT-LAMP assay targeting the ORF1a/1b gene, achieving a detection limit of 20 fg/µL with 100% concordance with conventional PCR in a blind clinical test of 81 effusion samples [65]. These isothermal methods are particularly well-suited for field deployment in shelters, catteries, and zoological facilities where rapid screening of large populations is required.

Immunochromatographic and Serological Approaches: Rapid Screening and Antibody Detection

The development of rapid immunochromatographic strips (ICS) has addressed the need for simple, instrument-free diagnostics that can be performed in any veterinary clinic. Zhang et al. (2025) developed a colloidal gold-based ICS utilizing monoclonal antibodies (mAbs) against the highly conserved N protein [6]. The assay demonstrated 98.3% agreement with RT-PCR in detecting 60 suspected samples, with a sensitivity capable of detecting FIPV suspensions diluted to 1:512 (TCID₅₀ = 10⁶.⁵/mL). The strip remained stable for six months at room temperature, making it logistically practical for global distribution [6]. Liu et al. (2025) similarly developed a double-antibody sandwich ICS using mAbs 2G7 and 3H5, which recognize distinct epitopes on the N protein (amino acids 18–28 and 295–323, respectively) [8]. This assay achieved a detection limit of 209.8 ng/mL for recombinant N protein, with 70% agreement with conventional PCR in ascites samples and no cross-reactivity with other feline viruses [8].

Serological testing for anti-FCoV antibodies remains a valuable adjunct, particularly for epidemiological surveillance and risk assessment. The indirect fluorescent antibody test (IFAT) has long been considered the gold standard, but enzyme-linked immunosorbent assays (ELISAs) offer superior throughput and objectivity. Ferrero et al. (2025) developed a novel indirect ELISA, FCoVCHECK Ab, which demonstrated 93.5% sensitivity and 100% specificity compared to IFAT, with 96.4% overall agreement [9]. The assay provides results within one hour, uses safe reagents, and has a shelf life of 18 months at 2–8°C, making it optimal for veterinary practice [9]. However, it is critical to recognize that seropositivity merely indicates prior exposure to FCoV, not necessarily FIP. In endemic populations, seroprevalence can exceed 90% [32], rendering a single positive antibody test diagnostically non-specific for FIP. The diagnostic value of serology is enhanced when interpreted in conjunction with clinical signs, hematological abnormalities, and the albumin-to-globulin (A:G) ratio. Sasvari et al. (2026) reported a neutralizing antibody seroprevalence of 13.6% and overall seroprevalence of 59.5% in 1,117 UK cats, with no significant impact of sex, age, or breed on neutralizing titers [32]. These data underscore the ubiquity of FCoV exposure and the necessity of multimodal diagnostic algorithms.

Mutation Detection: The Quest for the Pathogenic Signature

A central tenet of FIP pathogenesis is the "internal mutation theory," wherein benign FECV acquires specific genetic alterations that confer the ability to replicate within macrophages, leading to systemic dissemination [22, 26]. The identification of these mutations has been a major focus of diagnostic research, with the spike (S) protein gene receiving the most intense scrutiny. The S1/S2 furin cleavage site (FCS) and the fusion domain have been identified as hotspots for mutations associated with FIP development [26, 53]. Zehr et al. (2023) employed sophisticated molecular evolutionary statistical techniques to identify two sites exhibiting differences in natural selection pressure between FECV and FIPV: one within the S1/S2 FCS and another within the fusion domain [26]. They further identified 15 sites under positive selection associated with FIPV within Spike, 11 of which were previously unreported, falling within subdomains involved in receptor interaction, immune evasion, and tropism shifts [26].

The M1058L mutation in the S protein has garnered particular attention as a potential diagnostic marker. Zhu et al. (2023) analyzed S and 3c gene mutations in healthy and FIP cats from Beijing, finding the M1058L mutation in 13.64% of feces from FIP cats but in none from healthy cats [30]. Importantly, all parenteral samples (ascites, pleural effusions, tissues) from FIP cats carried one or more of the M1058L mutation, S1060A mutation, or a mutated 3c gene [30]. Lin et al. (2021) reported that 94.68% of 94 FCoV isolates from FIP-suspected cats in China harbored the M1058L mutation [40]. However, the diagnostic utility of these mutations is not absolute. Jähne et al. (2022) conducted a critical evaluation of commercial S gene mutation RT-qPCR assays in 87 cats without FIP (confirmed by histopathology and immunohistochemistry) and found that while the commercial assay detected S gene mutations in 14/21 FCoV RNA-positive cats, sequencing did not confirm mutated FCoV in any of these cases [64]. This discrepancy highlights the risk of false positives when relying solely on mutation-specific assays and underscores the importance of sequencing confirmation.

The emergence of the highly pathogenic FCoV-23 recombinant in Cyprus has introduced a new dimension to mutation-based diagnostics. Attipa et al. (2025) reported that a near-cat-specific deletion in domain 0 of the S protein is present in more than 90% of cats with FIP during this epizootic [5]. Olarte-Castillo et al. (2026) retrospectively identified similar within-host deletions in domain 0 of FCoV-2 from US cases, proposing that the "short version" of spike is generated within each cat after prolonged infection and spreads rapidly throughout the body, while the "long version" is transmitted between cats [36]. These findings suggest that domain 0 deletions may represent a novel class of pathogenic markers, though their association with disease development requires further elucidation.

The Diagnostic Challenge of Neurological and Ocular FIP

FIP involving the central nervous system (CNS) or eyes presents a particularly daunting diagnostic challenge, as effusions are typically absent and routine molecular testing of blood may be negative. Felten et al. (2021) evaluated the diagnostic value of detecting FCoV RNA and spike gene mutations in cerebrospinal fluid (CSF) from 30 cats with confirmed FIP (six with neurological signs) and 29 controls [42]. The sensitivity of 7b-RT-qPCR in CSF was 83.3% for cats with neurological FIP but only 16.7% for those without neurological involvement, indicating that CSF analysis is highly specific for CNS disease but not sensitive for detecting systemic FIP [42]. Spike gene mutations were rarely detected in CSF, suggesting that screening for these mutations does not enhance specificity in this patient population [42].

Pineda et al. (2024) explored the role of the eye as a potential gateway for systemic FCoV spread, analyzing 193 aqueous humor samples from cats with uveitis [49]. Sequencing of the S gene region coding for positions 1058 and 1060 revealed that the M1058L and S1060A mutations were significantly associated with severe disease, but ocular samples from cats with uveitis alone were more likely to contain FECV [49]. These findings suggest that while ocular FCoV detection can support a diagnosis of FIP in the appropriate clinical context, the presence of uveitis alone does not necessarily indicate systemic disease.

Machine Learning-Based Predictive Models: The New Frontier

The complexity and heterogeneity of FIP clinical presentation have made it an ideal candidate for the application of machine learning (ML) algorithms. As Dunbar (2025) articulates, "Utilising Machine Learning on clinical datasets could help to crack the enigma of feline infectious peritonitis diagnosis" [2]. The fundamental premise is that ML models can integrate multiple clinical, hematological, biochemical, and molecular parameters to generate a probabilistic diagnosis that outperforms any single test.

The development of such models requires large, well-annotated datasets. The nationwide study by Barua et al. (2024), with 14,035 samples, provides the statistical power necessary for training robust algorithms [16]. Logistic regression analyses from this study identified key risk factors, age (particularly 0–1 year), male sex, purebred status (British Shorthairs with OR: 2.81), and sample type, that can serve as input features for predictive models [16]. Gülersoy et al. (2023) contributed critical clinicopathological data, demonstrating that cats with effusive FIP exhibit significantly lower pH, HCO₃, and magnesium levels, higher base excess and lactate, and distinct patterns in serum alpha-1 acid glycoprotein (AGP) concentrations [31]. These parameters, when integrated, could form the basis of a multivariate predictive algorithm.

The potential of ML extends beyond diagnosis to prognostic stratification and treatment monitoring. The work of Wanakumjorn et al. (2025) on mesenchymal stem cell therapy in FIP cats employed principal component analysis of serum cytokine profiles, identifying three distinct inflammatory mediator patterns that correlated with treatment response [50]. Such approaches could be operationalized into ML models that predict which cats are most likely to benefit from specific therapeutic regimens. Furthermore, the integration of viral genomic data, including mutation profiles, recombination breakpoints, and quasispecies diversity, into predictive models could enable real-time risk assessment for FIP development in FCoV-infected cats.

The Cyprus FCoV-23 epizootic provides a compelling case study for the utility of ML in outbreak settings. Epaminondas et al. (2026) analyzed 68 veterinarian-reported cases using a structured 31-item questionnaire, revealing that affected cats were older than typically reported (mean age 3.9 years) and that neurological manifestations were present in 35.3% of cases [45]. ML models trained on such epidemiological data could identify emerging patterns of disease, predict outbreak trajectories, and guide resource allocation for diagnostic testing and antiviral therapy.

Comparative Performance and Diagnostic Algorithms

The selection of diagnostic approach must be guided by the clinical context, available resources, and the specific question being addressed. For screening asymptomatic cats in multi-cat environments, fecal RT-qPCR or RT-LAMP targeting the N or M gene provides high sensitivity for detecting FCoV shedding [12, 63, 65]. For confirming FIP in cats with effusions, RT-qPCR on peritoneal or pleural fluid is the preferred method, with the PicoGene direct RT-qPCR system offering rapid results [34]. In cases where effusion is absent but FIP is strongly suspected, tissue biopsy with histopathology and immunohistochemistry remains the gold standard, though this is invasive and may not be feasible in all cases [10, 56].

The Rivalta test, a simple and inexpensive method for differentiating transudates from exudates, retains clinical utility as a screening tool. Gülersoy et al. (2023) reported that effusion white blood cell count was higher in cats with abdominal effusion compared to thoracic effusion, and that serum AGP levels were highest in the thoracic effusion group [31]. When combined with the A:G ratio (with <0.8 considered highly suggestive of FIP) [45], these parameters provide a rapid, low-cost diagnostic framework that can be deployed in any practice setting.

Adaszek et al. (2023) compared the sensitivity of rapid serological tests and PCR in diagnosing effusive FIP, finding that serological testing detected antibodies in 70% of PCR-positive effusion samples [41]. While serology alone is insufficient for diagnosis, a positive result in effusion fluid, combined with compatible clinical signs and a low A:G ratio, significantly increases the probability of FIP.

Future Directions and Unresolved Challenges

Despite the remarkable advances in diagnostic technology, several critical challenges remain. The distinction between FECV and FIPV at the molecular level is not always clear-cut, as mutations associated with FIP can be detected in healthy cats and, conversely, some cats with FIP may harbor viruses lacking canonical mutations [64]. The work of Zehr et al. (2023) suggests that FIP development is unlikely to result from a single "switch" mutation but rather from a combination of genetic alterations that collectively alter viral pathogenesis [26]. This complexity necessitates a shift from binary diagnostic thinking (FIP vs. not FIP) to probabilistic risk stratification.

The emergence of recombinant viruses, such as FCoV-23, highlights the dynamic nature of FCoV evolution and the need for continuous surveillance and diagnostic assay updates [5, 24]. The domain 0 deletion identified in the Cyprus outbreak may represent a novel virulence marker, but its prevalence and significance in other geographic regions remain to be determined [36].

Finally, the integration of machine learning into routine clinical practice faces barriers related to data standardization, model interpretability, and validation across diverse populations. The development of open-access, multi-institutional databases that include clinical, laboratory, genomic, and outcome data will be essential for training and validating predictive models that can be deployed globally. As the field moves toward precision veterinary medicine, the diagnostic approach to FCoV and FIP will increasingly rely on the synthesis of molecular data, immunological profiling, and computational analytics to guide clinical decision-making in real time.

Therapeutic Advances and Management Strategies for a Previously Fatal Disease

For decades, a diagnosis of feline infectious peritonitis (FIP) was tantamount to a death sentence. The disease, characterized by a pernicious systemic pyogranulomatous inflammation, was considered invariably fatal, with therapeutic options limited to palliative care and euthanasia. However, the last five years have witnessed a revolutionary paradigm shift in the management of FIP, transforming it from a uniformly lethal condition into a treatable, and often curable, disease. This transformation has been driven primarily by the repurposing and clinical application of potent antiviral agents, most notably nucleoside analogs and protease inhibitors, and is further augmented by a growing understanding of immunomodulatory strategies that address the complex host-pathogen dynamics underlying FIP pathogenesis.

The Dawn of Antiviral Therapy: GS-441524 and GC376

The cornerstone of modern FIP therapeutics is the nucleoside analog GS-441524, the active metabolite of the prodrug remdesivir. The mechanistic underpinnings of its efficacy are deeply rooted in the viral replication cycle. GS-441524 is a competitive substrate for the viral RNA-dependent RNA polymerase (RdRp). Once incorporated into the nascent viral RNA chain, it acts as a delayed chain terminator, effectively halting viral replication [1, 15, 21]. This mechanism is not unique to FCoV; remdesivir has been a critical therapeutic option for SARS-CoV-2 infection in humans, underscoring the translational relevance of FIP as a model for coronavirus disease [21, 70]. The molecular target, the RdRp, is highly conserved across coronaviruses, which explains the broad-spectrum potential of this class of drugs.

The efficacy of GS-441524 against FIP has been established through a series of rigorous in vitro and in vivo studies. Schmied et al. [15] utilized a serotype I FCoV replicon system to demonstrate that GS-441524, alongside the main protease (Mpro) inhibitor GC376 and nirmatrelvir, were potent inhibitors of viral replication, with 50% cytotoxic concentrations (CC50) exceeding their half-maximal inhibitory concentrations (IC50) by more than 200-fold, indicating a wide therapeutic window. This in vitro data laid the groundwork for clinical application. Critically, the transition from a laboratory tool to a life-saving clinical therapy was propelled by studies demonstrating its oral bioavailability. A pivotal field study by Addie et al. [25] reported that a 4–7 day course of oral GS-441524 successfully eliminated fecal FCoV shedding in naturally infected cats, preventing the subsequent development of FIP in 147 cats from 27 households over a follow-up period of up to 3.5 years. This was a landmark finding, as it showed that early intervention to eliminate the virus could effectively prevent the emergence of the fatal disease.

Concurrent with the development of nucleoside analogs, protease inhibitors targeting the viral main protease (Mpro), also known as 3C-like protease (3CLpro), emerged as a powerful therapeutic class. The Mpro is responsible for cleaving the viral polyprotein into functional non-structural proteins, an essential step for viral replication. GC376, a prodrug that is converted to its active form GC373, irreversibly inhibits Mpro by forming a covalent bond with the catalytic cysteine residue (Cys144) in the active site [69]. Crystallographic studies by Lu et al. [69] provided atomic-level detail of this interaction, revealing that GC376 binds with high affinity and specificity to FCoV Mpro, with lower nanomolar Ki values than observed for SARS-CoV and SARS-CoV-2 Mpro. This structural insight not only confirmed the mechanism of action but also provided a foundation for structure-guided drug optimization.

The clinical utility of GC376 was further validated in a series of in vitro and in vivo investigations. Cook et al. [62] screened 90 putative antiviral compounds and identified GC376 as one of the most effective monotherapies against FIPV serotype II, alongside GS-441524 and other novel compounds like EIDD-2081. The combination of GC376 with GS-441524 demonstrated additive, and in some cases, limited synergistic, antiviral effects, though monotherapy was ultimately determined to be the most effective strategy for inhibiting viral transcription in their in vitro model [62]. The in vivo application of these agents has been nothing short of transformative. The clinical success of oral formulations, such as Mutian Xraphconn (which contains GS-441524), has been documented in numerous studies. Meli et al. [37] demonstrated that a 12-week oral treatment with Mutian Xraphconn effectively cured 18 cats with naturally occurring FIP, with treated cats showing a rapid decline in viral RNA loads in blood, effusions, and feces, with all cats becoming fecal-negative by day 6 of treatment. The emergence of a rapidly spreading outbreak of a highly pathogenic FCoV-CCoV recombinant (FCoV-23) in Cyprus further underscored the critical role of these antivirals. Attipa et al. [5, 24] reported that the FCoV-23 strain, which caused an epizootic affecting cats of all ages, was amenable to treatment with GS-441524. Epaminondas et al. [45] documented that of 68 veterinarian-reported FIP cases during this epizootic, 92.2% received antiviral therapy (GS-441524 or molnupiravir), with 88.9% showing clinical improvement. These findings collectively affirm that GS-441524 and GC376 are not merely experimental compounds but have become the standard-of-care drugs for FIP, offering a cure for a disease that was previously untreatable.

Beyond Direct-Acting Antivirals: Immunomodulation and Host-Directed Therapy

While direct-acting antivirals (DAAs) are the primary driver of clinical cure, the pathogenesis of FIP is inextricably linked to a dysregulated and overexuberant host immune response. The transition from asymptomatic FCoV infection to fatal FIP involves a complex interplay of viral mutation (enabling macrophage tropism) and a late-stage, ineffective T-cell response [27, 47]. This has opened the door for host-directed therapies that aim to modulate the immune system, mitigating the immunopathological damage that characterizes the disease.

One of the most promising adjunctive strategies is mesenchymal stem/stromal cell (MSC) therapy. The rationale for MSCs stems from their potent immunomodulatory and tissue-repair properties. In a landmark study by Wanakumjorn et al. [50], allogeneic MSC therapy was combined with antiviral treatment in cats with effusive FIP. The results were profound: MSC-treated cats exhibited enhanced immune recovery, characterized by a reduction in T-cell exhaustion markers (PD-1, TIM-3, LAG-3), decreased expression of exhaustion-related transcription factors (IKZF2, ZEB2, PRDM1), and an increase in regulatory T-cell (Treg) populations, which are crucial for restoring immune homeostasis. Single-cell RNA sequencing of mesenteric lymph nodes revealed transcriptomic shifts indicative of immune rejuvenation, including elevated memory T-cell markers and reduced hyperproliferative lymphocyte subsets [50]. This suggests that MSCs are not merely a supportive therapy but actively reprogram the aberrant immune response. A separate case series by Mohamadian et al. [67] reported the successful treatment of three FIP cats using only allogeneic bone marrow MSCs, with full recovery within 21 days. While one cat was re-infected after exposure to an infected cat, the other two remained in remission. These data, while preliminary, suggest that MSC therapy may have standalone efficacy in some cases, potentially by directly dampening the cytokine storm and promoting a more regulated, protective immune response.

The immunological basis for these interventions is further illuminated by studies on the PD-1/PD-L1 immune checkpoint axis. Zabiegala et al. [27] demonstrated that FIPV infection, but not FECV infection, significantly upregulates PD-L1 expression on infected macrophages. This upregulation, driven by type I interferon signaling, leads to the attenuation of T-cell activation via PD-1 engagement, creating a state of local immune exhaustion that permits persistent viral replication in macrophages. By targeting this pathway, either directly through checkpoint inhibitors or indirectly through MSC-induced Treg expansion, it may be possible to restore the functional T-cell response necessary for viral clearance. This aligns with the transcriptomic data from Malbon et al. [47], which showed that FIP cats exhibit a downregulation of T-cell-related processes in mesenteric lymph nodes, a finding not observed in FCoV-infected cats that did not develop FIP.

Other novel host-directed strategies are under investigation. The aryl hydrocarbon receptor (AhR) has emerged as a potential therapeutic target. Sorbo et al. [4] found that FCoV infection upregulates AhR signaling, and that the selective AhR antagonist CH223191 significantly reduces FCoV replication and viral nucleocapsid protein levels in vitro. This antiviral effect was linked to the alkalinization of lysosomes, suggesting that AhR antagonism may interfere with the endosomal trafficking required for viral entry and uncoating. This represents a completely new mechanism of action, distinct from both nucleoside analogs and protease inhibitors, and could be deployed in combination therapy to reduce the risk of resistance development.

Management Strategies and The Evolving Landscape

The translation of these therapeutic advances into clinical practice has necessitated a comprehensive re-evaluation of management strategies for FIP. The most critical shift is the emphasis on early diagnosis and treatment initiation. The availability of rapid, point-of-care diagnostics, such as colorimetric RT-LAMP assays [63, 65] and colloidal gold immunochromatographic strips targeting the N protein [6, 8], allows for same-day confirmation of FCoV infection in effusions or blood, enabling veterinarians to begin antiviral therapy without delay. The direct RT-qPCR system, PicoGene PCR1100, which omits RNA extraction and delivers results in ~40 minutes, is a prime example of a tool designed for this clinical urgency [34]. As Barua et al. [16] emphasized, optimizing sample selection, prioritizing peritoneal fluid, kidney, and lymph node samples, can dramatically improve detection rates and, by extension, the success of early intervention.

A key management principle that has emerged is the strategic use of antiviral therapy to prevent FIP development in high-risk populations. The study by Addie et al. [25] demonstrated that a short course of oral GS-441524 (4–7 days) administered to FCoV-shedding cats in multi-cat households was sufficient to eliminate shedding and prevent the emergence of FIP over a multi-year follow-up period. This has profound implications for the management of shelters and catteries, where FCoV is endemic and the risk of FIP is highest [18, 23]. The use of antiviral agents to break the cycle of fecal-oral transmission and environmental contamination is a proactive prophylactic strategy that directly addresses the epidemiological drivers of the disease.

Furthermore, the treatment of FIP is no longer a monolithic protocol. The clinical heterogeneity of the disease, ranging from effusive (wet) to non-effusive (dry) forms, and including ocular and neurological presentations, requires a nuanced approach. The CNS and eyes are considered immunologically privileged sites where drug penetration may be suboptimal, and where viral persistence and relapse are more likely. The emergence of FCoV-23 in Cyprus, with its high rate of neurological involvement (35.3% of cases in the Epaminondas et al. [45] study), underscores the need for drug regimens that can achieve therapeutic concentrations in these compartments. The use of molnupiravir, another RdRp inhibitor, in that outbreak suggests that alternative agents with different pharmacokinetic profiles may be required for certain disease presentations [45]. The development of advanced drug delivery systems, such as the rottlerin-liposome formulation described by Choi et al. [68], which enhances drug solubility and cellular uptake, represents a frontier in optimizing drug bioavailability to sanctuary sites.

Finally, the management of FIP must now also grapple with the specter of antiviral resistance. The use of monotherapy with GS-441524 or GC376 carries a theoretical risk of selecting for resistant viral mutants. The development of a versatile reverse genetics system for FCoV by Kida et al. [11] and Zhang et al. [66] provides a powerful platform for studying resistance-associated mutations in viral proteins such as the RdRp and Mpro. This tool will be essential for rational combination therapy design, mirroring the successful paradigms used for HIV and hepatitis C virus, where multi-drug regimens are standard to suppress viral replication and prevent resistance [62]. The in vitro work by Chou et al. [57] demonstrating that a plant extract from Vigna radiata (VRE) synergizes with both GS-441524 and GC376 against FCoV, including under conditions of antibody-dependent enhancement (ADE), hints at a future where adjunctive natural products could be used to enhance antiviral efficacy and reduce the required dose of DAAs, potentially mitigating toxicity and cost.

In summary, the therapeutic landscape for FIP has been utterly transformed. The disease is now a treatable infectious condition, managed with potent, targeted antivirals, and increasingly augmented by immunomodulatory therapies that restore host immune competence. The challenge for the field now lies in optimizing these regimens for all clinical forms of the disease, developing strategies to prevent the emergence of resistance, and translating these remarkable veterinary successes into broader lessons for coronavirus therapeutics in human and animal health.

References

[1] Dobie A, Bayrakal A, Or M, Bilge A. Dynamics of Feline Coronavirus and FIP: A Compartmental Modeling Approach. Veterinary Medicine International. 2023. DOI: https://doi.org/10.1155/2023/2721907

[2] Dunbar D. Feline coronavirus and feline infectious peritonitis (FIP) – Russian roulette for your pet. Open Access Government. 2025. DOI: https://doi.org/10.56367/oag-046-11915

[3] Li C, Liu Q, Kong F, Guo D, Zhai J, Su M, et al.. Circulation and genetic diversity of Feline coronavirus type I and II from clinically healthy and FIP‐suspected cats in China. Transboundary and Emerging Diseases. 2018. DOI: https://doi.org/10.1111/tbed.13081

[4] Sorbo LD, Giugliano R, Cerracchio C, Iovane V, Salvatore M, Serra F, et al.. In Vitro Evaluation of Aryl Hydrocarbon Receptor Involvement in Feline Coronavirus Infection. Viruses. 2025. DOI: https://doi.org/10.3390/v17020227

[5] Attipa C, Warr A, Epaminondas D, O’Shea M, Hanton AJ, Fletcher S, et al.. Feline infectious peritonitis epizootic caused by a recombinant coronavirus. Nature. 2025. DOI: https://doi.org/10.1038/s41586-025-09340-0

[6] Zhang M, Zhu Y, Li N, Aishanjiang K, Zhu S, Tang A, et al.. Development of a monoclonal antibody-based colloidal gold immunochromatographic strip for rapid detection of feline coronavirus.. International Journal of Biological Macromolecules. 2025. DOI: https://doi.org/10.1016/j.ijbiomac.2025.142683

[7] Amalia F, Wasissa M, Salasia S, Lestari FB. Detection and Genetic Analysis of Feline Coronavirus in Clinically Suspected Cats. World's Veterinary Journal. 2025. DOI: https://doi.org/10.54203/scil.2025.wvj82

[8] Liu Z, Yang Y, Qi R, Gu H, Chen M, Feng K, et al.. A colloidal gold immunochromatographic test strip based on mAbs anti-N protein to detect feline coronavirus. Microbiology spectrum. 2025. DOI: https://doi.org/10.1128/spectrum.01830-24

[9] Ferrero I, Dewilde S, Poletti P, Canepa B, Giachino E, Dall'Ara P, et al.. Development of a New Indirect ELISA Test for the Detection of Anti-Feline Coronavirus Antibodies in Cats. Veterinary Sciences. 2025. DOI: https://doi.org/10.3390/vetsci12030245

[10] Mohammadzadeh P, Ziaee F, Mousavi F. Molecular and pathological confirmation of natural feline coronavirus infection in a captive persian leopard (Panthera pardus tulliana): Implications for Wildlife conservation and one health. Open Veterinary Journal. 2025. DOI: https://doi.org/10.5455/OVJ.2025.v15.i9.83

[11] Kida I, Tamura T, Kuroda Y, Fukuhara T, Maeda K, Matsuno K. Application of versatile reverse genetics system for feline coronavirus. Microbiology spectrum. 2025. DOI: https://doi.org/10.1128/spectrum.02692-24

[12] Kopduang C, Rapichai W, Leangcharoenpong C, Khamsingnok P, Puangmalee T, Ratanabunyong S, et al.. Detection of Feline Coronavirus Membrane Gene Based on Conventional Revere Transcription-Polymerase Chain Reaction, Nested Reverse Transcription-Polymerase Chain Reaction, and Reverse Transcription-Quantitative Polymerase Chain Reaction: A Comparative Study. International Journal of Molecular Sciences. 2025. DOI: https://doi.org/10.3390/ijms26146861

[13] Olarte‐Castillo XA, Goodman LB, Whittaker GR. Molecular detection using hybridization capture and next-generation sequencing reveals cross-species transmission of feline coronavirus type-1 between a domestic cat and a captive wild felid. bioRxiv. 2024. DOI: https://doi.org/10.1128/spectrum.00061-24

[14] Stout AE, André N, Whittaker G. FELINE CORONAVIRUS AND FELINE INFECTIOUS PERITONITIS IN NONDOMESTIC FELID SPECIES. Journal of zoo and wildlife medicine. 2021. DOI: https://doi.org/10.1638/2020-0134

[15] Schmied K, Ehmann R, Kristen-Burmann C, Ebert N, Barut G, Almeida L, et al.. An RNA replicon system to investigate promising inhibitors of feline coronavirus. Journal of Virology. 2024. DOI: https://doi.org/10.1128/jvi.01216-23

[16] Barua S, Sarkar S, Chenoweth K, Johnson C, Delmain D, Wang C. Insights on feline infectious peritonitis risk factors and sampling strategies from polymerase chain reaction analysis of feline coronavirus in large-scale nationwide submissions.. Journal of the American Veterinary Medical Association. 2024. DOI: https://doi.org/10.2460/javma.24.03.0208

[17] Park Y, Kim C, Park Y, Lee S, So J, Park R, et al.. Compound C inhibits the replication of feline coronavirus. Heliyon. 2024. DOI: https://doi.org/10.1016/j.heliyon.2024.e27641

[18] Addie D. Feline infectious peritonitis: answers to frequently asked questions concerning FIP and coronavirus. Veterinary Nursing Journal. 2019. DOI: https://doi.org/10.1080/17415349.2019.1629366

[19] Kida I, Tamura T, Kuroda Y, Fukuhara T, Maeda K, Matsuno K. First versatile reverse genetics system for feline coronavirus. bioRxiv. 2024. DOI: https://doi.org/10.1101/2024.10.02.616382

[20] Wang Y, Wang J, Zhao Y, Liu Y, Zhang M, Deng X, et al.. Isolation and Genomic Characteristics of a Novel Pathogenicity Type I Feline Coronavirus in Mainland China. Transboundary and Emerging Diseases. 2024. DOI: https://doi.org/10.1155/2024/4162458

[21] Paltrinieri S, Giordano A, Stranieri A, Lauzi S. Feline infectious peritonitis (FIP) and coronavirus disease 19 (COVID‐19): Are they similar?. Transboundary and Emerging Diseases. 2020. DOI: https://doi.org/10.1111/tbed.13856

[22] Gao Y, Wang Q, Liang X, Zhang S, Bao D, Zhao H, et al.. An updated review of feline coronavirus: mind the two biotypes. Virus Research. 2023. DOI: https://doi.org/10.1016/j.virusres.2023.199059

[23] Berliner EA. Feline Coronavirus and Feline Infectious Peritonitis. Infectious Disease Management in Animal Shelters. 2021. DOI: https://doi.org/10.1002/9781119294382.ch16

[24] Attipa C, Warr A, Epaminondas D, O’Shea M, Hanton AJ, Fletcher S, et al.. Emergence and spread of feline infectious peritonitis due to a highly pathogenic canine/feline recombinant coronavirus. bioRxiv. 2024. DOI: https://doi.org/10.1101/2023.11.08.566182

[25] Addie D, Bellini F, Covell-Ritchie J, Crowe B, Curran S, Fosbery M, et al.. Stopping Feline Coronavirus Shedding Prevented Feline Infectious Peritonitis. Viruses. 2023. DOI: https://doi.org/10.3390/v15040818

[26] Zehr JD, Pond SKK, Millet J, Olarte‐Castillo XA, Lucaci AG, Shank SD, et al.. Natural selection differences detected in key protein domains between non-pathogenic and pathogenic feline coronavirus phenotypes. Virus Evolution. 2023. DOI: https://doi.org/10.1093/ve/vead019

[27] Zabiegala A, Kim Y, Chang K. Differential induction of PD-L1 expression in cells infected with feline infectious peritonitis virus and feline enteric coronavirus.. Virology. 2025. DOI: https://doi.org/10.1016/j.virol.2025.110734

[28] Tekelioglu BK. Seroepidemiological and Clinicopathological Study of Feline Coronavirus (FCoV) and Feline Infectious Peritonitis (FIP), Could Guide to SARS-CoV-2 (COVID-19) in ‘One Health’ Approach. Alinteri Journal of Agricultural Sciences. 2020. DOI: https://doi.org/10.47059/ALINTERI/V35I2/AJAS20092

[29] Kokkinaki KG, Saridomichelakis M, Mylonakis M, Leontides L, Xenoulis P. Seroprevalence of and risk factors for feline coronavirus infection in cats from Greece.. Comparative Immunology, Microbiology & Infectious Diseases. 2023. DOI: https://doi.org/10.2139/ssrn.4258563

[30] Zhu J, Deng S, Mou D, Zhang G, Fu Y, Huang W, et al.. Analysis of spike and accessory 3c genes mutations of less virulent and FIP-associated feline coronaviruses in Beijing, China.. Virology. 2023. DOI: https://doi.org/10.1016/j.virol.2023.109919

[31] Gülersoy E, Ok M, Üney K, Durgut M, Parlak TM, Ekici YE. Comparison of Clinical and Laboratory Findings at Different Clinical Stages in Cats Naturally Infected with Feline Coronavirus. Acta Veterinaria. 2023. DOI: https://doi.org/10.2478/acve-2023-0003

[32] Sasvari H, Sherry L, Logan N, Dunbar D, Tyson GB, Tait-Burkard C, et al.. Serological response to feline coronavirus in the UK domestic cat population. Journal of General Virology. 2026. DOI: https://doi.org/10.1099/jgv.0.002270

[33] Izofani S, Wasissa M. The emerging landscape of feline coronavirus type II in Asia: A review of molecular diversity and diagnostic challenges. BIO Web of Conferences. 2026. DOI: https://doi.org/10.1051/bioconf/202622901014

[34] Doki T, Yonezawa Y, Katayama M, To K, Takano T. Clinical evaluation of a direct RT-qPCR method for feline coronavirus detection in effusions using the PicoGene PCR1100 system. Journal of Veterinary Diagnostic Investigation. 2026. DOI: https://doi.org/10.1177/10406387251411275

[35] Carlton C, Norris JM, Miranda LHMd, Westman M, Hall E, Atkin N, et al.. EXPRESS: Low incidence of feline infectious peritonitis in rehomed shelter cats with known feline coronavirus status: a cohort study of 767 cats. Journal of feline medicine and surgery. 2026. DOI: https://doi.org/10.1177/1098612x261447040

[36] Olarte‐Castillo XA, Schlecht AB, Sams K, Goodman LB, Whittaker GR. Identification of within-host deletions in domain 0 of the spike gene of pathogenic feline coronavirus type 2 from the USA. Journal of feline medicine and surgery. 2026. DOI: https://doi.org/10.1177/1098612X261433664

[37] Meli M, Spiri A, Zwicklbauer K, Krentz D, Felten S, Bergmann M, et al.. Fecal Feline Coronavirus RNA Shedding and Spike Gene Mutations in Cats with Feline Infectious Peritonitis Treated with GS-441524. Viruses. 2022. DOI: https://doi.org/10.3390/v14051069

[38] Cook SE, Castillo D, Williams S, Haake CJE, Murphy B. Serotype I and II Feline Coronavirus Replication and Gene Expression Patterns of Feline Cells, Building a Better Understanding of Serotype I FIPV Biology. Viruses. 2022. DOI: https://doi.org/10.3390/v14071356

[39] Ratti G, Stranieri A, Giordano A, Oltolina M, Bonacina E, Magnone W, et al.. Molecular Detection of Feline Coronavirus in Captive Non-Domestic Felids from Zoological Facilities. Animals. 2022. DOI: https://doi.org/10.3390/ani12141864

[40] Lin L, Yao D, Wu L, Fan R, Liu Y, Zhou Z. Molecular epidemiology of type I and II feline coronavirus from cats with suspected feline infectious peritonitis in China between 2019 and 2021. Archives of Virology. 2021. DOI: https://doi.org/10.1007/s00705-021-05291-9

[41] Adaszek Ł, Kalinowski M, Rutkowska-Szulczyk M, Mazurek Ł, Szulc D, Staniec M, et al.. Comparison of the sensitivity of rapid tests, FCoV Ab (Vet Expert) and PCR, in the diagnosis of feline infectious peritonitis (FIP) in cats with the effusive form of the disease. Medycyna Weterynaryjna. 2023. DOI: https://doi.org/10.21521/mw.6745

[42] Felten S, Matiasek K, Leutenegger C, Sangl L, Herre S, Dörfelt S, et al.. Diagnostic Value of Detecting Feline Coronavirus RNA and Spike Gene Mutations in Cerebrospinal Fluid to Confirm Feline Infectious Peritonitis. Viruses. 2021. DOI: https://doi.org/10.3390/v13020186

[43] Drechsler Y, Vasconcelos E, Griggs L, Diniz P. Host responses to feline coronavirus are significantly different in primary macrophages compared to CRFK cells.. Journal of Immunology. 2021. DOI: https://doi.org/10.4049/jimmunol.206.supp.19.13

[44] Addie D, Curran S, Bellini F, Crowe B, Sheehan EM, Ukrainchuk L, et al.. Oral Mutian®X stopped faecal feline coronavirus shedding by naturally infected cats. Research in Veterinary Science. 2020. DOI: https://doi.org/10.1016/j.rvsc.2020.02.012

[45] Epaminondas D, Mazeri S, Lyraki M, Tait-Burkard C, Gunn-Moore D, Loukaidi S, et al.. Epidemiological and Clinical Insights from 68 Veterinarian-Reported Cases of Feline Infectious Peritonitis During the Documented FIP Epizootic in Cyprus. Pathogens. 2026. DOI: https://doi.org/10.3390/pathogens15050499

[46] Jaimes JA, Whittaker G. Feline coronavirus: Insights into viral pathogenesis based on the spike protein structure and function. Virology. 2018. DOI: https://doi.org/10.1016/j.virol.2017.12.027

[47] Malbon AJ, Russo G, Burgener CJ, Barker EN, Meli M, Tasker S, et al.. The Effect of Natural Feline Coronavirus Infection on the Host Immune Response: A Whole-Transcriptome Analysis of the Mesenteric Lymph Nodes in Cats with and without Feline Infectious Peritonitis. Pathogens. 2020. DOI: https://doi.org/10.3390/pathogens9070524

[48] Takano T, Akiyama M, Doki T, Hohdatsu T. Antiviral activity of itraconazole against type I feline coronavirus infection. Veterinary Research. 2019. DOI: https://doi.org/10.1186/s13567-019-0625-3

[49] Pineda A, Lavergne E, Brauge C, Laveran E, Bertagnoli S, Boucraut-Baralon C, et al.. Feline coronavirus-associated uveitis: The eye as a gateway to systemic spread and feline infectious peritonitis?. Veterinary Microbiology. 2024. DOI: https://doi.org/10.1016/j.vetmic.2024.110355

[50] Wanakumjorn P, Kimura K, Castillo D, McLarty E, Formaker R, Qiao R, et al.. Mesenchymal stem/stromal cell therapy improves immune recovery in a feline model of severe coronavirus infection. Stem Cells Translational Medicine. 2025. DOI: https://doi.org/10.1093/stcltm/szaf025

[51] Zehr JD, Pond SKK, Millet J, Olarte‐Castillo XA, Lucaci AG, Shank SD, et al.. Natural selection differences detected in key protein domains between non-pathogenic and pathogenic Feline Coronavirus phenotypes. bioRxiv. 2023. DOI: https://doi.org/10.1101/2023.01.11.523607

[52] Malbon AJ, Meli M, Barker EN, Davidson AD, Tasker S, Kipar A, et al.. Inflammatory Mediators in the Mesenteric Lymph Nodes, Site of a Possible Intermediate Phase in the Immune Response to Feline Coronavirus and the Pathogenesis of Feline Infectious Peritonitis?. Journal of Comparative Pathology. 2018. DOI: https://doi.org/10.1016/j.jcpa.2018.11.001

[53] Ouyang H, Liu J, Yin Y, Cao S, Yan R, Ren Y, et al.. Epidemiology and Comparative Analyses of the S Gene on Feline Coronavirus in Central China. Pathogens. 2022. DOI: https://doi.org/10.3390/pathogens11040460

[54] Tuanthap S, Chiteafea N, Rattanasrisomporn J, Choowongkomon K. Comparative sequence analysis of the accessory and nucleocapsid genes of feline coronavirus strains isolated from cats diagnosed with effusive feline infectious peritonitis. Archives of Virology. 2021. DOI: https://doi.org/10.1007/s00705-021-05188-7

[55] Tanaka Y, Tanabe E, Sasaki T. Near-complete genome sequencing of the feline coronavirus serotype I strain FIPV-Aqua from a cat with feline infectious peritonitis in Japan. Microbiology Resource Announcements. 2025. DOI: https://doi.org/10.1128/mra.00357-25

[56] Healey E, André N, Miller AD, Whitaker GR, Berliner EA. Outbreak of feline infectious peritonitis (FIP) in shelter-housed cats: molecular analysis of the feline coronavirus S1/S2 cleavage site consistent with a ‘circulating virulent–avirulent theory’ of FIP pathogenesis. JFMS open reports. 2022. DOI: https://doi.org/10.1177/20551169221074226

[57] Chou A, Lin C, Chang Y, Chang H, Lin Y, Pi C, et al.. Antiviral activity of Vigna radiata extract against feline coronavirus in vitro. Veterinary Quarterly. 2024. DOI: https://doi.org/10.1080/01652176.2024.2349665

[58] Zanutto M, Toda K, Silva DDd. The use of antivirals for the treatment of feline infectious peritonitis (FIP). Clínica Veterinária. 2025. DOI: https://doi.org/10.46958/rcv.2025.xxx.n.179.p.44-76

[59] Gülersoy E, Ok M, Üney K, Durgut M, Parlak TM, Ekici YE. Intestinal injury and vasculitis biomarkers in cats with feline enteric coronavirus and effusive feline infectious peritonitis. Veterinary Medicine and Science. 2023. DOI: https://doi.org/10.1002/vms3.1299

[60] Amalia F, Wasissa M, Salasia S, Lestari FB. Combined molecular and clinicopathologic characterization of feline coronavirus infection in cats from a multicat shelter. Jurnal Medika Veterinaria. 2026. DOI: https://doi.org/10.20473/jmv.vol9.iss1.2026.259-271

[61] Rana EA, Akther M, Beetson S, Sarker S, Rossi G, Uddin J. Successful in vitro propagation of feline coronavirus from clinically diagnosed feline infectious peritonitis cases using Vero cells: A potential model for future research.. Veterinary Record Open. 2026. DOI: https://doi.org/10.1002/vro2.70030

[62] Cook SE, Vogel H, Castillo D, Olsen M, Pedersen N, Murphy B. Investigation of monotherapy and combined anticoronaviral therapies against feline coronavirus serotype II in vitro. Journal of feline medicine and surgery. 2021. DOI: https://doi.org/10.1177/1098612X211048647

[63] Khumtong K, Rapichai W, Saejung W, Khamsingnok P, Meecharoen N, Ratanabunyong S, et al.. Colorimetric Reverse Transcription Loop-Mediated Isothermal Amplification with Xylenol Orange Targeting Nucleocapsid Gene for Detection of Feline Coronavirus Infection. Viruses. 2025. DOI: https://doi.org/10.3390/v17030418

[64] Jähne S, Felten S, Bergmann M, Erber K, Matiasek K, Meli M, et al.. Detection of Feline Coronavirus Variants in Cats without Feline Infectious Peritonitis. Viruses. 2022. DOI: https://doi.org/10.3390/v14081671

[65] Rapichai W, Saejung W, Khumtong K, Boonkaewwan C, Tuanthap S, Lieberzeit P, et al.. Development of Colorimetric Reverse Transcription Loop-Mediated Isothermal Amplification Assay for Detecting Feline Coronavirus. Animals. 2022. DOI: https://doi.org/10.3390/ani12162075

[66] Zhang X, Zhu J, Zhang D, Zhang Y. Development of a yeast-based CRISPR genome editing system for feline coronavirus. Frontiers in Microbiology. 2025. DOI: https://doi.org/10.3389/fmicb.2025.1627509

[67] Mohamadian S, Kazerooni P, Mirghaed AT, Kia M, Soltani M, Akbaripazouki A, et al.. Successful Treatment of Feline Infectious Peritonitis Disease (FIP) with Mesenchymal Stem Cells. Iranian Journal of Veterinary Medicine. 2025. DOI: https://doi.org/10.32598/ijvm.19.2.1005555

[68] Choi J, Jung S, Choi I, Kang Y, Lee D, Lee S, et al.. Rottlerin-Liposome Inhibits the Endocytosis of Feline Coronavirus Infection. Veterinary Sciences. 2023. DOI: https://doi.org/10.3390/vetsci10060380

[69] Lu J, Chen S, Khan MB, Brassard R, Arutyunova E, Lamer T, et al.. Crystallization of Feline Coronavirus Mpro With GC376 Reveals Mechanism of Inhibition. Frontiers in Chemistry. 2022. DOI: https://doi.org/10.3389/fchem.2022.852210

[70] Delaplace M, Huet H, Gambino A, Poder SL. Feline Coronavirus Antivirals: A Review. Pathogens. 2021. DOI: https://doi.org/10.3390/pathogens10091150